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Abstract 
Teemu Ahola, Antihypertensive drug therapy in Finland. Utilization of 
antihypertensive medication, control of blood pressure, and achievable reduction of 
cardiovascular morbidity with intensified treatment. 
National Institute for Health and Welfare. Research 103. 167 pages. Turku, Finland 
2013. 
ISBN 978-952-245-861-2 (printed); ISBN 978-952-245-862-9 (online publication) 
 
Hypertension has been identified as one of the major risk factors causing premature 
death. According to earlier studies, antihypertensive drugs have been underused and 
control of hypertension is proven to be poor in Finland and some other countries. It 
is well known that lowering blood pressure significantly reduces cardiovascular 
morbidity and mortality. According to national and international guidelines, 
antihypertensive drug therapy is chosen individually after taking into account 
indication, cardiovascular risk profile, target organ damages, and coexisting 
disorders. Healthy lifestyle also has a significant role in the treatment of 
hypertension. However, combination antihypertensive medication is usually 
required to reach the target blood pressure. Still, limited data exists on the utilization 
of antihypertensive drugs and drug combinations (including triple therapy) in 
relation to concomitant comorbidities in nationwide population studies, and in 
Finland such data, practically, does not exist. 
 
The purpose of this thesis was to assess the prevalence and control of hypertension 
and the rationality of treatment (i.e., drug selection and drug combinations in 
accordance with national and international guidelines) among at least 30 years old 
patients with diabetes (I), coronary heart disease (II), and uncomplicated essential 
hypertension (III); and to assess changes in antihypertensive medication between 
2000 and 2006. In addition, living habits associated with increased risk of 
cardiovascular disease were assessed, and the expected reduction of strokes and 
ischaemic heart disease events of uncomplicated hypertensive patients were 
calculated in theory by intensifying antihypertensive medication for those with 
uncontrolled BP ( ≥ 140/90 mmHg) (III). In the last study (IV), differences in drug 
therapy were compared between those entitled to reimbursement for hypertension 
medication cost and those without this entitlement. New onset diseases during the 
follow-up time were also noted. Moreover, differences in drug therapy in 2006 
between recently treated and formerly treated were assessed after adjustment with 
age, sex, and living area (IV). 
 
The material was based on two different data. The data of Health 2000 Survey were 
based on a well-representative sample of Finnish adult population (n=6209, 30-99 
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years old). Subjects participated in interviews, a thorough clinical health 
examination and laboratory analyses between 2000 and 2001. The massive database 
of the Social Insurance Institution (SII) of Finland included the data of prescriptions 
and the entitlements to drug reimbursement for medication costs (in 2000-2001 and 
in 2006-2007) and included 1.59 million Finnish patients aged 30 years or older. In 
addition to the above, the database of SII included practically 100% of the 
prescriptions on antihypertensive and lipid-lowering drugs purchased by the Finnish 
population between September 1st and November 30th in 2000 and 2006.  
 
Results of this thesis indicate that control of BP at the beginning of the 2000s has 
been alarmingly poor. On the contrary, between 2000 and 2006, monotherapy 
decreased while combination therapy, particularly that of three or more 
antihypertensive drugs, increased significantly. Utilization of evidence-based drug 
therapies, particularly angiotensin receptor blockers among adult hypertensive 
patients increased significantly by the end of 2006. Despite the positive change 
discovered in this study, underutilization of antihypertensive drugs and poor control 
of hypertension still remain a matter of concern. Beyond that, there seems to be an 
unceasing relative overuse of beta-blockers in the treatment of hypertension, 
especially among diabetic patients and uncomplicated hypertensive patients. 
Moreover, quite surprisingly, beta-blockers seem to be chosen as first line agents far 
more often than other antihypertensive agents, even among recently treated 
hypertensive patients without compelling indication for their use. However, as 
calculated in this study, intensifying the treatment of uncomplicated hypertensive 
patients by one-half standard dose of BP-lowering regimen for those whose BP 
exceeded the limit of 140/90 mmHg, would increase the control of hypertension 
from 34% to 48%, reduce strokes by 18%, and reduce ischaemic heart disease 
events by 13%. 
 
According to the results of this thesis, it can be concluded that more rational 
selections of antihypertensive drugs and drug combinations are needed. Physicians 
should take into account more precisely related or absent comorbidities, 
cardiovascular risk factors and other individual characteristics when choosing 
antihypertensive agents for hypertensive patients. Results of this thesis can be 
utilized in daily clinical practices, in order to benefit Finnish physicians and 
hypertensive patients in the long run.  
 
Keywords: blood pressure, drug therapy, hypertension, diabetes, coronary heart 
disease, uncomplicated essential hypertension, cardiovascular morbidity, 
combination therapy  
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Tiivistelmä 
Teemu Ahola, Kohonneen verenpaineen lääkehoito Suomessa. 
Verenpainelääkkeiden käyttö, verenpaineen hallinta, ja tehostetulla hoidolla 
saavutettavissa oleva sydän- ja verisuonisairauksien vähentyminen. 
Terveyden ja hyvinvoinnin laitos. Tutkimus 103. 167 sivua. Turku, Finland 2013. 
ISBN 978-952-245-861-2 (painettu); ISBN 978-952-245-862-9 (verkkojulkaisu) 
 
Kohonnut verenpaine on identifioitu yhdeksi tärkeimmistä ennenaikaista 
kuolleisuutta aiheuttavista riskitekijöistä. Verenpainelääkkeet ovat olleet 
alikäytettyjä ja verenpaineen hoitotavoitteessa mukana olevien osuus on todettu 
pieneksi sekä Suomessa että muissa maissa. Tiedetään myös, että verenpaineen 
alentaminen vähentää merkitsevästi sydän- ja verisuonisairauksia sekä kuolleisuutta. 
Kansallisen ja kansainvälisten hoitosuositusten mukaan verenpaineen lääkehoito 
valitaan yksilöllisesti käyttötarkoitus, potilaan riskitekijät, kohde-elinvauriot ja 
liitännäissairaudet huomioiden. Myös terveellisten elintapojen merkitys korostuu 
kohonneen verenpaineen hoidossa. Hoitotavoitteeseen pääsy edellyttää kuitenkin 
useimmiten lääkeyhdistelmien käyttöä. Silti väestötason tutkimuksia verenpaineen 
lääkehoidosta ja yhdistelmähoidosta (mukaan lukien kolmen verenpainelääkkeen 
yhdistelmät) liitännäissairauksiin suhteutettuna on käytettävissä toistaiseksi hyvin 
niukasti, ja Suomesta nämä käytännössä puuttuvat. 
 
Tutkimuksen tavoitteena oli selvittää vähintään 30-vuotiaiden, diabetesta (I), 
sepelvaltimotautia (II) ja essentiaalista komplisoitumatonta kohonnutta 
verenpainetta (III) sairastavien suomalaisten kohonneen verenpaineen esiintyvyyttä, 
hoitoisuutta ja hoidon rationaalisuutta (lääkevalintoja ja -yhdistelmiä suhteessa 
kansallisiin ja kansainvälisiin hoitosuosituksiin) sekä arvioida hoidossa tapahtuneita 
muutoksia vuosina 2000–2006. Lisäksi selvitettiin valtimotaudin riskiin liittyviä 
elintapoja em. kohderyhmissä (I-III) sekä arvioitiin, kuinka paljon 
komplisoitumatonta essentiaalista kohonnutta verenpainetta sairastavien henkilöiden 
sydän- ja aivoinfarkteja voitaisiin teoriassa vähentää tehostamalla verenpaineen 
lääkehoitoa niillä, joiden verenpaine ei ollut hoitotavoitteessa (RR≥140/90 mmHg) 
(III). Viimeisessä osatyössä (IV) verrattiin verenpainelääkevalintoja 
erityiskorvausoikeutettujen ja oikeuttamattomien henkilöiden välillä.  Myös 
seuranta-aikana ilmaantuneet uudet liitännäissairaudet huomioitiin. Lisäksi verrattiin 
vuoden 2006 lääkevalintoja uusien ja pidempään verenpaineen lääkehoidossa 
olleiden potilaiden välillä niin, että ikä, sukupuoli ja alue oli vakioitu (IV).  
 
Tutkimukseen käytettiin kahta aineistoa. Terveys 2000 tutkimusaineisto perustui 
edustavaan suomalaiseen aikuisväestöotokseen (n = 6209, 30–99-vuotiasta 
henkilöä). Tutkimushenkilöt osallistuivat vuosina 2000–2001 haastatteluihin, 
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perusteelliseen kliiniseen terveystarkastukseen sekä laboratoriotutkimuksiin. Kelan 
reseptitiedoista ja erityiskorvausrekistereistä (2000–2001 ja 2006–2007) koottu 
jättiaineisto käsitti yhteensä 1,59 miljoonaa vähintään 30-vuotiasta suomalaista. 
Erityiskorvausrekisterien lisäksi Kelan aineisto sisälsi 100 % kaikista verenpaine- ja 
kolesterolilääkeostoista Suomessa syyskuun alusta marraskuun loppuun vuosilta 
2000 ja 2006. 
 
Tämän väitöstutkimuksen tulokset osoittavat, että verenpaineen hoitotavoitteessa 
olleiden osuus oli hälyttävän pieni 2000-luvun alussa. Toisaalta vuosina 2000-2006 
monoterapian osuus väheni ja yhdistelmähoito, etenkin vähintään kolmen 
verenpainelääkkeen yhdistelmien osalta, lisääntyi huomattavasti. Näyttöön 
perustuvien terapioiden, erityisesti angiotensiinireseptorin salpaajien käyttö, lisääntyi 
huomattavasti vuoden 2006 loppuun mennessä. Tutkimuksessa todetuista 
positiivisista muutoksista huolimatta verenpainelääkkeiden liian vähäinen käyttö ja 
taudin hoitotavoitteessa mukana olevien pieni osuus huolestuttavat edelleen. Lisäksi 
beetasalpaajien suhteellinen yliedustus kohonneen verenpaineen hoidossa näyttää 
jatkuvan etenkin diabeetikoilla ja essentiaalista komplisoitumatonta kohonnutta 
verenpainetta sairastavilla. Oli melko yllättävää, että jopa uusille 
verenpainepotilaille määrättiin ensilinjan lääkkeenä kaikista verenpainelääkkeista 
muita useammin beetasalpaajia, vaikka ehdotonta indikaatiota sen käytölle ei 
ollutkaan. Toisaalta, kuten tässä tutkimuksessa osoitettiin, tehostamalla 
essentiaalista komplisoitumatonta kohonnutta verenpainetta sairastavien hoitoa 
lisäämällä tarvittaessa vain puolikas verenpainelääkeannos niille, joiden verenpaine 
ylitti rajan 140/90 mmHg, voitaisiin hoitotavoitteessa olevien osuutta lisätä 34 %:sta 
48 %:iin ja samalla vähentää aivoinfarkteja 18 %:lla ja iskeemisiä sydäntapahtumia 
13 %:lla. 
 
Tämän tutkimuksen perusteella voidaan todeta, että verenpaineen hoitoon 
käytettävien lääkkeiden valinnan tulisi olla rationaalisempaa. Lääkäreiden tulisi 
verenpainelääkkeitä valitessaan tarkemmin huomioida potilaan liitännäissairaudet, 
sydän- ja verisuonisairauksien riskitekijät sekä muut yksilölliset tekijät. Tämän 
väitöskirjan tuloksia voidaan soveltaa suoraan kliiniseen käytännön työhön 
lääkäreiden avuksi ja potilaiden parhaaksi.   
 
Avainsanat: verenpaine, lääkehoito, kohonnut verenpaine, diabetes, 
sepelvaltimotauti, komplisoitumaton essentiaalinen kohonnut verenpaine, sydän- ja 
verisuonitautisairastuvuus, yhdistelmälääkehoito 
 
 
 
THL — Research 103, 2013 11 Antihypertensive Drug Therapy in Finland 
 
Contents 
ABSTRACT ................................................................................................................ 7	  
TIIVISTELMÄ ........................................................................................................... 9	  
LIST OF ORIGINAL PUBLICATIONS .................................................................. 14	  
ABBREVIATIONS .................................................................................................. 15	  
1 INTRODUCTION ................................................................................................. 19	  
2 REVIEW OF THE LITERATURE ....................................................................... 21	  
2.1 BP threshold for drug therapy according to guidelines ................................. 21	  
2.1.1 Patients with essential hypertension (including uncomplicated   
         hypertensive patients) ............................................................................ 21	  
2.1.2 Diabetic patients .................................................................................... 22	  
2.1.3 Coronary heart disease patients ............................................................. 23	  
2.2 Target blood pressure according to guidelines .............................................. 32	  
2.2.1 Patients with essential hypertension (including uncomplicated  
         hypertensive patients) ............................................................................ 32	  
2.2.2 Diabetic patients .................................................................................... 32	  
2.2.3 Coronary heart disease patients ............................................................. 33	  
2.3 Antihypertensive medication according to guidelines .................................. 35	  
2.3.1 Patients with essential hypertension ...................................................... 35	  
     2.3.1.1 Initial antihypertensive medication ............................................... 35	  
     2.3.1.2 Combination antihypertensive medication .................................... 37	  
2.3.2 Diabetic patients .................................................................................... 39	  
     2.3.2.1 Initial antihypertensive medication ............................................... 39	  
     2.3.2.2 Combination antihypertensive medication .................................... 40	  
2.3.3 Coronary heart disease patients ............................................................. 43	  
     2.3.3.1 Initial antihypertensive medication ............................................... 43	  
     2.3.3.2 Combination antihypertensive medication .................................... 44	  
2.3.4 Uncomplicated hypertensive patients ................................................... 46	  
2.4 Prevalence of hypertension and control of BP in population-based studies . 48	  
2.4.1 General population ................................................................................ 48	  
2.4.2 Diabetic patients .................................................................................... 51	  
2.4.3 Coronary heart disease patients ............................................................. 53	  
2.4.4 Uncomplicated hypertensive patients ................................................... 55	  
2.5 Utilization of antihypertensive drugs in population-based studies ................ 55	  
2.5.1 General population ................................................................................ 55	  
2.5.2 Diabetic patients .................................................................................... 56	  
     2.5.2.1 Monotherapy ................................................................................. 56	  
     2.5.2.2 Combination therapy ..................................................................... 57	  
2.5.3 Coronary heart disease patients ............................................................. 59	  
2.5.4 Uncomplicated hypertensive patients ................................................... 59	  
 
 
THL — Research 103, 2013 12 Antihypertensive Drug Therapy in Finland 
 
3 AIMS OF THE STUDY ........................................................................................ 61	  
4 MATERIALS AND METHODS ........................................................................... 62	  
4.1 Study designs and populations ...................................................................... 62	  
4.1.1 The Health 2000 Survey ........................................................................ 62	  
4.1.2 Database of the Social Insurance Institution ......................................... 65	  
4.2 Drug therapy .................................................................................................. 66	  
4.3 Blood pressure measurement ......................................................................... 66	  
4.4 Laboratory analyses ....................................................................................... 67	  
4.5 Electrocardiography ...................................................................................... 67	  
4.6 Medical history .............................................................................................. 67	  
4.7 Definitions ..................................................................................................... 68	  
4.7.1 The Health 2000 Survey ........................................................................ 68	  
4.7.2 Database of the Social Insurance Institution ......................................... 69	  
4.8 Control of hypertension and estimated reduction of BP and cardiovascular  
      morbidity ....................................................................................................... 70	  
4.9 Statistical analyses ......................................................................................... 70	  
5 RESULTS .............................................................................................................. 73	  
5.1 Characteristics of study population ............................................................... 73	  
5.1.1 Study I (Diabetic patients) .................................................................... 73	  
5.1.2 Study II (CHD patients) ........................................................................ 73	  
5.1.3 Study III (Uncomplicated hypertensive patients) ................................. 73	  
5.1.4 Study IV ................................................................................................ 74	  
     5.1.4.1 Subjects with uncomplicated mild hypertension ........................... 74	  
     5.1.4.2 Subjects with moderate to severe hypertension ............................ 74	  
     5.1.4.3 Formerly diagnosed moderately to severely hypertensive 
                 subjects .......................................................................................... 74	  
     5.1.4.4 Recently diagnosed moderately to severely hypertensive 
                 subjects .......................................................................................... 74	  
5.2 Prevalence, treatment, and control of hypertension (I-III) ............................ 74	  
5.2.1 The Health 2000 Survey ........................................................................ 74	  
5.2.2 Database of the Social Insurance Institution ......................................... 76	  
5.3 Estimated control of hypertension and reduction of BP and cardiovascular  
      morbidity, with intensified antihypertensive treatment, among 
      uncomplicated hypertensive subjects (III) ..................................................... 76	  
5.4 Antihypertensive drug therapy in Finland between 2000 and 2006 .............. 78	  
5.4.1 Diabetic patients (I) ............................................................................... 78	  
5.4.2 CHD patients (II) ................................................................................... 78	  
5.4.3 Uncomplicated hypertensive patients (III) ............................................ 79	  
5.5 Changes in the utilization of antihypertensive drugs and concomitant 
      diseases on the individual level between 2000 and 2006 (IV) ...................... 79	  
5.5.1 Subjects with moderate to severe hypertension .................................... 79	  
5.5.2 Subjects with uncomplicated mild hypertension ................................... 80	  
 
 
THL — Research 103, 2013 13 Antihypertensive Drug Therapy in Finland 
 
5.6 Differences in utilization of antihypertensive medication in 2006 between  
      recently and formerly diagnosed subjects with moderate to severe  
      hypertension (IV) ........................................................................................... 80	  
6 DISCUSSION ........................................................................................................ 82	  
6.1 Utilization of antihypertensive drugs and control of hypertension among 
      diabetic patients in Finland between 2000 and 2006 (I) ................................ 82	  
6.2 Utilization of antihypertensive drugs and control of hypertension among 
      CHD patients in Finland between 2000 and 2006 (II) .................................. 84	  
6.3 Utilization of antihypertensive drugs, control of hypertension and achievable 
      reduction in BP and cardiovascular morbidity among uncomplicated  
      hypertensive patients in Finland between 2000 and 2006 (III) ..................... 86 
6.4 Beta-blockers are relatively overused in Finland (IV) .................................. 88	  
6.5 Limitations ..................................................................................................... 91	  
7 SUMMARY AND CONCLUSIONS .................................................................... 93	  
8 ACKNOWLEDGEMENTS ................................................................................... 95	  
REFERENCES ......................................................................................................... 98	  
ORIGINAL PUBLICATIONS ............................................................................... 111	  
 
 
THL — Research 103, 2013 14 Antihypertensive Drug Therapy in Finland 
 
List of original publications 
This thesis is based on the following original articles  referred to in the text by their 
Roman numerals. 
I Ahola TL, Jula AM, Kantola IM, Mäki J, Klaukka T, Reunanen A. Positive 
change in the utilization of antihypertensive and lipid-lowering drugs among 
adult diabetics in Finland. Results from large national database between 2000 
and 2006. J Hypertens 2009, 27:2283-2293. 
II Ahola TL, Kantola IM, Puukka P, Kattainen A, Klaukka T, Reunanen A, Jula 
AM. Positive change in the utilization of antihypertensive and lipid-lowering 
drugs among adult CHD patients in Finland: results from a large national 
database between 2000 and 2006. Eur J Cardiovasc Prev Rehabil 2010, 
17:477-485. 
III Ahola TL, Kantola IM, Mäki J, Reunanen A, Jula AM. Adding a low-dose 
antihypertensives regimen would substantially improve the control of 
hypertension and reduce cardiovascular morbidity among uncomplicated 
hypertensive patients. Eur J Prev Cardiol 2012, 19:712-722. 
IV Ahola TL, Jula AM, Kantola IM, Puukka P. Beta-blockers are relatively 
overused in Finland. Submitted. 
 
The original papers in this thesis have been reproduced with permission of the 
copyright holders. 
 
 
THL — Research 103, 2013 15 Antihypertensive Drug Therapy in Finland 
 
Abbreviations 
ABCD Appropriate Blood Pressure Control in Non-insulin-dependent 
Diabetes Mellitus 
ACCOMPLISH Avoiding Cardiovascular Events in Combination Therapy in 
Patients Living with Systolic Hypertension 
ACCORD Action to Control Cardiovascular Risk in Diabetes 
ACTION A Controlled Trial Investigating Outcomes of Exercise Training 
ADVANCE Action in Diabetes and Vascular Disease: Preterax and 
Diamicron MR Controlled Evaluation 
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial 
ANBP2 Second Australian National Blood Pressure Study 
ACE AngiotensinConverting Enzyme 
ARB Angiotensin Receptor Blocker 
ASA Acetylsalicylic Acid 
ASCOT Anglo-Scandinavian Cardiac Outcomes Trial 
BB Beta-blocker 
BENEDICT Bergamo Nephrologic Diabetes Complications Trial 
BHS British Hypertension Society 
BMI Body Mass Index 
BP Blood Pressure 
CABG Coronary Artery Bypass Grafting 
CAFE Conduit Artery Function Evaluation 
CAMELOT Comparison of Amlodipine vs. Enalapril to Limit Occurrences 
of Trombosis 
CAPPP Captopril Prevention Project 
CCB Calcium Channel Blocker 
CHD Coronary Heart Disease 
CHF Chronic Heart Failure 
DAVIT The Danish Verapamil Infarction Trial 
ELSA European Lacidipine Study on Atherosclerosis 
ESC European Society of Cardiology 
ESH European Society of Hypertension 
EUROASPIRE European Action on Secondary Prevention through Intervention 
to Reduce Events 
EUROPA European Trial on Reduction of Cardiac Events with Perindopril 
in Stable Coronary Artery Disease 
FACET Fosinopril Versus Amlodipine Cardiovascular Events 
Randomized Trial 
FCCH Finnish Current Care Hypertension 
 
 
THL — Research 103, 2013 16 Antihypertensive Drug Therapy in Finland 
 
FDMS Formerly Diagnosed Moderately to Severely 
FEVER Felodipine Event Reduction 
FHA Finnish Heart Association 
H2000 Health 2000 Survey 
HDL High Density Lipoprotein 
HOPE Heart Outcomes Prevention Evaluation 
HOT Hypertension Optimal Treatment 
HYVET Hypertension in the Very Elderly Trial 
IDNT Irbesartan Diabetic Nephropathy Trial 
IHD Ischaemic Heart Disease 
INSIGHT International Nifedipine GITS Study: Intervention as a Goal in 
Hypertension Treatment 
INVEST International Verapamil Sustained Release Trandolapril Study 
IRMA-2 IRbesartan in MicroAlbuminuria, Type 2 Diabetic Nephropathy 
I-SEARCH International Survey Evaluation Microalbuminuria Routinely by 
Cardiologist in patients with Hypertension 
JIKEI Heart Japanese Investigation of Kinetic Evaluation in Hypertensive 
Event and Remodeling Treatment 
JNC6 Sixth Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
JNC7 Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure 
JMIC-B Japan Multicenter Investigation for Cardiovascular Diseases-B 
MDPIT Multicenter Diltiazem Post-Infarction Trial 
NHANES National Health and Nutrition Examination Survey 
NORDIL Nordic Diltiazem Study 
LDL Low Density Lipoprotein 
LIFE Losartan Intervention for Endpoint Reduction 
ONTARGET Ongoing Telmisartan Alone and in Combination with Ramipril 
Global Endpoint Trial 
OPTIMAAL Optimal Trial in Myocardial Infarction with the Angiotensin II 
Antagonist 
PEACE Prevention of Events with Angiotensin-Converting Enzyme 
Inhibition 
PREVESE Secondary Prevention of Myocardial Infarction in Spain 
PTCA Percutaneus Transluminal Coronary Angioplasty 
QUIET Quinapril Ischemic Event Trial 
RAS Renin-Angiotensin System 
RDMS Recently Diagnosed Moderately to Severely 
RENAAL Reduction of Endpoints in NIDDM with the Angiotensin II 
Antagonist Losartan 
SCOPE Study on Cognition and Prognosis in the Elderly 
 
 
THL — Research 103, 2013 17 Antihypertensive Drug Therapy in Finland 
 
SHEP Systolic Hypertension in the Elderly Program 
SII  Social Insurance Institution of Finland (Kela) 
STOP-2  Swedish Trial in Old Patients with Hypertension-2 
Syst-Eur Systolic Hypertension in Europe 
TASPIC-CRO  Treatment and Secondary Prevention of Ischemic Coronary 
events in Croatia 
TNT An analysis of the Treating to New Targets 
TRANSCEND Telmisartan Randomized Assessment Study in ACE Intolerant 
Subjects with Cardiovascular Disease  
UKPDS United Kingdom Prospective Diabetes Study Group 
VALIANT Valsartan in Acute Myocardial Infarction Trial 
VALUE Valsartan Antihypertensive Long-term Use Evaluation 
VHAS Verapamil in Hypertension and Atherosclerosis Study 
WHO-ISH World Health Organization – International Society of 
Hypertension 
 
 
THL — Research 103, 2013 19 Antihypertensive Drug Therapy in Finland 
 
1 Introduction 
Hypertension has been identified as the leading risk factor for mortality 1. 
Antihypertensive drugs are underused, and control of hypertension is poor both in 
Finland and some other countries 2-5.  
 
While some drugs and drug combinations may be more efficient at reducing 
cardiovascular morbidity, no category of drugs appears to be inferior in their ability 
to reduce BP 6, 7. Many studies support the view that the reduction of BP per se is 
more important than the individual properties of the specific drug, for decreasing 
cardiovascular risk among hypertensive patients 8-10. There is evidence that lowering 
systolic BP by 10 mmHg or diastolic BP by 5 mmHg reduces events of stroke by 
approximately 41% and of ischaemic heart disease (ICH) by approximately 22% 11. 
 
According to national and international guidelines, each agent can be preferentially 
prescribed under specific conditions 12-15. However, combination therapy is usually 
required to achieve a proper control of BP 7. Nevertheless, the European Society of 
Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for 
management of arterial hypertension 16, published in 2003, demonstrated evidence 
that specific drug classes may differ in some effect, or in special groups of patients. 
Beyond that, national 12, 13 and international guidelines 16 have emphasized that 
physicians should tailor a drug treatment to an individual patient after taking into 
account the cardiovascular risk profile, target organ damages, and other coexisting 
disorders (renal disease, diabetes, etc.). ESH and ESC guidelines for the 
management of arterial hypertension 16 also listed indications and contraindications 
for the major classes of antihypertensive drugs. Moreover, the guidelines 
emphasized the importance of low-dose combination therapy and established the 
renoprotective effects of ACE inhibitors and ARBs 13, 16. According to recent 
guidelines, the most rational three-drug combination appears to be a blocker of 
renin-angiotensin system (RAS), a calcium channel blocker (CCB), and a diuretic, 
although other drugs, such as a beta-blocker (BB) or an alpha-blocker, may be used 
in specific indications, depending on the clinical circumstances 7.  
 
However, the available data is limited, if any, on the utilization of antihypertensive 
drugs and drug combinations (including triple therapy) in relation to concomitant 
comorbidities in all-inclusive nationwide studies.  In Finland, such data, practically, 
does not exist. 
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The aim of this thesis was to assess the utilization of antihypertensive drugs in 
Finland between 2000 and 2006, and to assess trends in the utilization of 
antihypertensive drugs and drug combinations among diabetic patients, CHD 
patients, and uncomplicated hypertensive patients. The ultimate purpose was to 
assess whether these treatments are in line with the guidelines of hypertension 
management. Beyond that, the longitudinal nationwide drug utilization study 
presented in this thesis analyzes changes in monotherapy, in dual-therapy, and in 
drug combinations containing at least three drugs, in relation with changes in 
concomitant disease profiles on the individual level. In addition, this thesis was also 
designed to assess the control of hypertension in above-named subgroups, and to 
calculate the expected reductions in BP and cardiovascular morbidity among 
uncomplicated hypertensive patients, with intensified antihypertensive treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THL — Research 103, 2013 21 Antihypertensive Drug Therapy in Finland 
 
2 Review of the Literature 
2.1 BP threshold for drug therapy according to guidelines 
2.1.1 Patients with essential hypertension (including uncomplicated  
         hypertensive patients) 
 
Typical for hypertension management guidelines in the nineties and early 2000s was 
a fairly conservative approach in relation to initiation of antihypertensive drug 
therapy. Even at relatively high levels of BP, such as 140-159/90-99 mmHg, drug 
treatment was recommended to be started with lifestyle modifications and non-
pharmacological interventions. If this, after several months of follow-up including 
re-measurements of BP, did not achieve required targets, initiation of 
antihypertensive drug therapy was recommended. For the general population (those 
without additional cardiovascular risk factors), the mean BP of 160/100 mmHg was 
the most common threshold for drug therapy during the nineties 17 and early 2000s 
12. However, each guideline categorized BP levels into certain ranges and gave 
specific recommendation as to when to commence antihypertensive medication. 
Specific BP thresholds and/or ranges of systolic and diastolic BP for initiation of 
drug therapy, taking into account target organ damages and cardiovascular risk 
levels, are presented in detail in Table 1 (columns “General population” and 
“Uncomplicated hypertension”).  The Finnish Current Care Hypertension (FCCH) 
guidelines (2002) 12 placed significant importance on target organ damages and 
other cardiovascular risk factors. Evaluation of cardiovascular risk, particularly in 
the ESH guidelines (2003) 16, took a very important role instead of a certain BP 
value in itself.  In addition, the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC7) 18, recommended for the 
first time to initiate treatment of hypertension with a two-drug combination instead 
of monotherapy if the BP exceeded 160/100 mmHg.  
 
The ESH/ESC guidelines (2007) 19 emphasized individual cardiovascular risk 
beyond BP level, in the evaluation of treatment strategy. In brief, between 1994 and 
2009, the guidelines have moved slowly into more aggressive initiation of 
antihypertensive pharmacotherapy.  There are numerous studies from the past 
twenty years, which have affected the development of these guidelines and when to 
initiate antihypertensive drug therapy.  Of these McMahon et al. 20, Collins et al. 11, 
the meta-analysis of Staessen et al. 21, Vasan et al. 22, the meta-analysis of 
Lewington et al. 23, the STOP trial 24,  MRC trial 25, SHEP trial 26, Syst-Eur trial 27, 
HOT trial 28, VALUE trial 29, FEVER trial 30, and ASCOT trial 31, are the most 
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important. See also Table 2 (Description of major clinical trials of primary 
hypertensives).  
 
Worth mentioning is also the fact that the guidelines for initiation of 
antihypertensive medication among uncomplicated hypertensive patients have 
departed from those for “General” hypertensive patients but not earlier than in the 
ESH/ESC guidelines published in 2007. 
 
2.1.2 Diabetic patients 
 
According to the Finnish Heart Association (FHA) working group recommendation 
(the current national guideline during the health 2000 Survey) published in 1994 32, 
the BP threshold for drug therapy was not separately specified for diabetic patients.  
The recommendation followed the same principals as made for general hypertensive 
patients. In 1997, the sixth report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC6) 17 gave for the 
first time a specific recommendation for the initiation of antihypertensive 
medication for diabetic patients. The JNC6 set the threshold to 130-139 mmHg for 
systolic BP and 85-89 mmHg for diastolic BP. In 2002, the FCCH guidelines 12 set 
the BP threshold for drug therapy to 140/90 mmHg for diabetic patients; however, 
the FCCH guidelines recommended to consider treatment with BP 130-139/85-89 
mmHg in the case of Type 1 diabetes or renal failure.   
 
In 2003, ESH guidelines 16 lowered the threshold limit to 130/85 mmHg, and the 
JNC7 18 accordingly, to 130/80 mmHg. The FCCH guidelines in 2005 13, however, 
kept the previous slightly higher threshold of 140/90 mmHg. 
 
Due to poor and somewhat controversial trial evidence, the ESH guidelines 
increased the threshold for initiation of drug therapy back to the level of 140/90 
mmHg in 2009 7. Besides, it reappraised that initiation of BP-lowering treatment in 
the high normal BP range (130-139/85-89 mmHg) is unsupported by prospective 
trial evidence unless microalbuminuria or proteinuria is involved. The FCCH 
guidelines, published in 2009 14, hold the threshold of 140/90 mmHg for initiation of 
antihypertensive drug therapy.   
 
In brief, scientific evidence from randomized clinical trials led the guidelines in 
early 2000s and mid-2000s to recommend lowering the BP target for diabetic 
patients. Consequently, this forced to earlier initiation of antihypertensive treatment 
in addition to lifestyle modifications. Recommendations favouring more aggressive 
treatment were probably generated by some trials, such as the HOT trial 28, and the 
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post hoc analyses of the Syst-Eur trial 33. There are numerous other studies made in 
the course of the past twenty years, which have directly or indirectly affected the 
development of these guidelines. Collins et al. 11, Peterson et al. 34, Curb et al. 1996 
35, UKPDS38 36, UKPDS39 8, ABCD 37-39, the MICRO-HOPE substudy 40, the 
FEVER trial 30, and the ADVANCE trial, are the most important.  
Nonetheless, after the publication of recent guidelines, there is evidence that no 
benefit has been achieved for diabetic patients if the systolic BP is intensively 
lowered below 130 mmHg 41, 42, or below 120 mmHg 43, as compared with those 
with a target systolic BP <140 mmHg. According to the meta-analysis of Sarwar et 
al. 44 diabetes itself doubles the risk of vascular disease, independent of other 
conventional risk factors. 
 
Description of major clinical trials concerning hypertension and diabetes is shown in 
Table 3. See also Table 1 (BP thresholds for drug therapy according to guidelines 
from 1994 to 2009, column “DM”). 
 
2.1.3 Coronary heart disease patients 
 
Specific threshold values for systolic and diastolic BP, in the treatment guidelines 
between 1994 and 2009, for initiating drug therapy for hypertensive CHD patients, 
are presented in detail in Table 1, column “CHD”. In brief, BP threshold values for 
initiation of antihypertensive drug therapy for CHD patients have been in line with 
those for diabetic patients. However, the threshold slightly differs between these two 
groups of patients in some of the guidelines 12, 13, 45, as shown in Table 1. According 
to the FHA work group recommendation (1994) 32, the BP threshold for drug 
therapy was not separately specified for CHD patients and therefore followed the 
same principles as those for general hypertensive patients. In the early and mid 
2000s, the FCCH guidelines 12, 13 set the threshold BP for drug therapy for CHD to 
140/90 mmHg, while the ESH guidelines (2003) set the threshold 10/5 mmHg lower 
than the FCCH guidelines. Several studies have been published during the last few 
decades which are responsible for the development of the guidelines with respect to 
initiation of antihypertensive drug therapy for CHD patients. Some of these are 
already referred to in previous chapters; however, the HOPE trial 46, EUROPA trial 
47, CAMELOT study 48, ACTION trial 49, VALUE trial 29, and PEACE trial 50, are 
the ones most important.  See Table 4 (Description of major clinical trials 
concerning hypertension and CHD). 
 
Nonetheless, the ESH/ESC guidelines (2007) 19 recommended to consider initiation 
of drug therapy sometimes even at normal BP values, such as 120-129/80-84 
mmHg. Similarly, for diabetics, in case of CHD patients, these recommendations 
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have been reconsidered due to scant and somewhat controversial trial evidence 
described widely in recent ESH guidelines in 2009 7.   
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2.2 Target blood pressure according to guidelines 
2.2.1 Patients with essential hypertension (including uncomplicated  
         hypertensive patients) 
 
In the early nineties, the FHA working group recommendation 32 set the overall 
target of BP below 160/90 mmHg. However, it stated that the desirable BP for all 
patients should be below 130/85 mmHg. Accordingly, the World Health 
Organization – International Society of Hypertension (WHO-ISH) guideline 45, 
which was the current international guideline during the Health 2000 Survey, 
recommended that the target BP be below 140/90 mmHg. However, for young and 
middle-aged patients, it was remarked that the desirable BP should remain below 
130/85 mmHg. 
 
The general BP target below 140/85 mmHg for all hypertensive subjects was set by 
the FCCH guidelines in 2002 12. The JNC7 18, as well as the ESH/ESC retained the 
target BP below 140/90 mmHg for all hypertensive patients in their guidelines 
published in 2003 16. However, the guidelines recommended even lower values for 
all, if tolerated. The FCCH guidelines, updated in 2005 13, retained the target BP of 
less than 140 mmHg for systolic BP and less than 85 mmHg for diastolic BP, which 
was at that time the evidence-based target. For uncomplicated hypertensive s, the 
FCCH guidelines in 2005 retained the same target BP. 
 
Due to lack of trial evidence, especially for elderly patients, in 2009 the ESH 
guidelines 7 reappraised the target BP to 130-139/80-85 mmHg, even for those at 
high cardiovascular risk.  
 
There have been several studies in the past 15-20 years, which have lead into above 
recommendations. Among these, Collins et al. 1990 11, McMahon et al. 20, 
Lewington et al. 23, Vasan et al. 22, and a few randomized clinical trials (Table 2), of 
which especially Syst-Eur 27, the STOP trial 24, SHEP trial 26, HOT trial 28, VALUE 
trial 29, and FEVER trial 30 are the ones most important. For details, see Table 2. See 
also Table 5 (Target of clinical BP according to guidelines from 1994 to 2009, 
column “General population”). 
 
2.2.2 Diabetic patients 
 
According to the FHA working group, the recommendation (1994) for target BP for 
diabetic patients was as for the general population, below 160/90 mmHg.  In 1997 
the JNC6 17 and in 1999 the WHO-ISH 45, both set the target BP below 130/85 
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mmHg for diabetic patients. Benefits of tight BP control were demonstrated in the 
HOT trial 28, UKPDS38 36, UKPDS39 8, and ABCD trials 38, 39. Thereafter the 
FCCH guidelines 12 in 2002 determined a separate BP target, below 140/80 mmHg, 
although in case of renal disease or significant proteinuria, the target BP was set 
below 130/80 mmHg.  
The JNC7 18 and ESH guidelines 16 in 2003 lowered the target BP below 130/80 
mmHg. An update of the FCCH guidelines 13 in 2005 kept their previous BP goal 
below 140/80 mmHg for diabetic patients, however, in case of diabetic nephropathy, 
microalbuminuria, non-diabetic kidney disease, or significant proteinuria, the target 
was set below 130/80 mmHg. 
 
The ESH guidelines published in 2007 19, retained the BP target set in 2003.Due to 
lack of trial evidence the ESH guideline 7 stated in 2009 that the target BP 130-
139/80-85 mmHg for all, including high risk patients as diabetic patients, may be 
prudent. Although the reappraisal of the ESH guidelines raised heavy criticism due 
to controversial trial evidence, the target systolic BP for diabetic patients remained 
below 130 mmHg. Yet, it was stated clearly that SBP below 130 mmHg is not 
consistently supported by trial evidence. Despite that, during the same year, the 
Finnish national recommendation 14 lowered the target BP below 130/80 mmHg for 
diabetic patients and patients with renal disease to be in line with previously updated 
national guidelines 89 for management of diabetes. 
 
In addition to trials mentioned above, there have also been several other studies 
which directly or indirectly have guided the development of these recommendations. 
Among many other studies, such as Collins et al. 1990 11, Peterson et al. 1995 34, the 
post hoc analyses of the Syst-Eur trial 33, and  the post hoc subgroup analyses of the 
HOT trial 76 and FEVER trial  30 are the most important. For details, see Table 3. See 
also Table 5 (Target of clinical BP according to guidelines from 1994 to 2009, 
column “DM”). According to recent evidence, which has been published later than 
these guidelines, no benefit is gained, if the systolic BP is lowered further, below 
130 mmHg 41 or below 120 mmHg 43, as compared with those with a target systolic 
BP <140 mmHg. 
 
2.2.3 Coronary heart disease patients 
 
In 1994, the FHA working group 32 recommended a diastolic BP below 90 mmHg as 
target BP for CHD patients. However, diastolic BP consistently below 85 mmHg 
was not supported by this recommendation. In 1997, the JNC6 17 set the target BP 
below 140/90 mmHg and even lower if angina pectoris was present. The target BP 
for CHD patients remained below 140/90 mmHg according to guidelines of WHO-  
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ISH in 1999 45, FCCH in 2002 12, ESH in 2003 16, JNC7 in 2003 18, and FCCH in 
2005 13.  
 
In 2007, for the first time, the ESH/ESC guidelines 19 set the target BP below 130/80 
mmHg for patients at high or very high risk, especially for those having suffered MI 
or stroke.  
 
Several studies have made an impact on the recommendation of tight BP control for 
CHD patients. The ACTION trial 49, but also the VALUE trial 29, EUROPA trial 47, 
CAMELOT trial 48, and FEVER trial 30 showed benefits of lowering BP  to 
relatively low levels and are those most important. On the other hand, after the 
publication of the secondary analyses of data from the INVEST Study 90, the 
ONTARGET trial 91 and the TNT trial 92, which showed somewhat controversial 
trial evidence against previous recommendations due to the J-curve phenomenon, 
the reappraised ESH guidelines in 2009 7 raised substantial criticism. Consequently, 
it took a more conservative opinion by stating that the target BP in the range 130-
139/80-85 mmHg may be prudent for all, including high risk patients. In 2009, the 
FCCH guidelines 14 set the target BP below 130/80 mmHg only for those CHD 
patients who had a history of MI or stroke. For details, see Table 4. See also Table 5 
(Target of clinical BP according to guidelines from 1994 to 2009, column “CHD”). 
 
After the publication of recent guidelines, there is evidence that no benefit is 
achieved if the systolic BP is further lowered below 130 mmHg 41 except for those 
at high risk for stroke,  as compared with those with a target systolic BP of <140 
mmHg. 
 
2.3 Antihypertensive medication according to guidelines 
2.3.1 Patients with essential hypertension 
2.3.1.1 Initial antihypertensive medication 
 
Initial antihypertensive medication for (essential or primary) hypertension 
recommended by 12 guidelines from 1994 to 2009, is described in Table 6.  
 
The guidelines of the nineties (FHA working group 32 and JNC6 17) recommended 
initiating antihypertensive medication either with a diuretic or a BB unless 
contraindicated or there is a specific indication for another drug. In 2002, the FCCH 
guidelines 12 recommended the initiation of antihypertensive medication with low-
dose hydrochloride thiazides, ACE inhibitors, or BBs.  Also a CCB, in case of high 
systolic BP, was recommended as a first line agent.  The ESH guidelines in 2003 16 
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and the FCCH guidelines in 2005 13 stated that the treatment of hypertension can be 
initiated with all major antihypertensive agents, although a low-dose was 
recommended. However, JNC7 18, in 2003, recommended starting with a thiazide 
diuretic. The British Society of Hypertension (BHS) guidelines 52 in 2004 brought 
out the AB/CD algorithm, which was modified from the Cambridge AB/CD rule 93. 
The original Cambridge AB/CD rule recommended initiating antihypertensive 
medication either with those drugs which inhibit (ACE inhibitors/ARBs or BBs) or 
with those which do not inhibit (CCBs or diuretics) the renin-angiotensin system. 
The modified AB/CD algorithm was different for elderly patients and for those 
younger than 55 years. Moreover, it placed BBs within brackets by not preferring 
them as first-line agents for the treatment of hypertension, especially for elderly 
patients.  
 
Thereafter the ESH/ESC in 2007 19 and ESH in 2009 7 did not significantly depart 
from their earlier recommendations, although the role of thiazides was emphasized 
among diuretics. The ESH guidelines during the 2000s as well as the FCCH 
guidelines in 2009 14 indicated initiation with a two-drug combination for a first 
choice approach as an alternative to monotherapy, especially if BP was markedly 
elevated. The WHO-ISH 45 and JNC7 18 did not recommend a short-acting CCB, 
while the BHS guidelines in 1999 51 and the ESH/ESC guidelines in 2007 19 did not 
recommend high-dose thiazides for the initiation of antihypertensive medication. In 
addition, BBs, especially non-vasodilating ones, were not recommended as first-line 
agents by the ESH/ESC guidelines in 2007 19 and the FCCH guidelines in 2009 14, 
especially for patients with a metabolic syndrome or high risk for diabetes.  
 
In the early nineties, three trials, the STOP trial 24, the SHEP trial 26, and the MRC 
trial 53, showed significant effects in preventing cardiovascular morbidity and 
mortality when using low-dose diuretics or BBs as initial treatment. The results of 
prospectively designed overviews of randomized trials of Turnbull et al. 94 and the 
meta-analysis of Law et al. in 2009 95 have shown that treatment with any 
commonly used regimen reduces the risk of total major cardiovascular events. In 
addition, the Syst-Eur trial 27, CAPPP trial 55, and ONTARGET trial 67 showed the 
benefits of CCBs, ACE inhibitors, and ARBs as initial treatment of hypertension 
(Table 2).   
 
On the contrary, 2 meta-analyses, Lindholm et al. 96 and Wiysonge et al. 97, have 
shown evidence against BBs as a first-line choice in the treatment of primary 
hypertension. Third meta-analysis, Khan et al. 98 which compared BBs with other 
drugs, showed that BBs had a similar reduction in endpoints among patients less 
than 60 years old, but among elderly patients, treatment with BBs was associated 
with a superior risk of strokes, as compared with other antihypertensive agents. The 
meta-analysis of Bangalore et al. 99 showed that BBs are associated with an 
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increased risk for new-onset diabetes and with a 15% increased risk for stroke, as 
compared with other agents. According to Mancia et al. 100 thiazide diuretics seem to 
have dyslipidaemic and diabetogenic effects when used at high doses. The meta-
analysis of Elliot et al. 101 showed that the association with incident diabetes is 
highest with diuretics, followed by BBs, CCBs, ACE inhibitors, and ARBs. 
 
2.3.1.2 Combination antihypertensive medication 
 
Combination antihypertensive medication for (essential or primary) hypertension, 
recommended by 12 guidelines from 1994 to 2009, is described in Table 6. 
 
Since the late nineties, guidelines have emphasized that most hypertensive patients 
require a combination antihypertensive medication in order to reach the target BP. 
Most guidelines in the 2000s have emphasized the importance of a low-dose 
combination rather than increasing the dose of the initial regimen, in order to 
improve the efficacy and to reduce adverse effects. Practically in all of these 
guidelines, a diuretic- (or a thiazide)-based treatment has been the cornerstone of 
combination therapy. A clear trend towards preferring RAS blockers is seen in the 
guidelines of the late 2000s. Still, since 1999 until 2005, with an exception of the 
BHS guidelines 2004 52, a BB plus a diuretic (thiazide in JNC7 18) was on the list of 
recommended 2-drug therapies for initiation of combination antihypertensive 
medication. On the contrary, BHS guidelines 2004 did not recommend BBs to be 
used as primary drugs for initiation of combination therapy. Besides, according to 
recently published ESH guidelines, a BB combined with a thiazide (in ESH/ESC 
2007 19) or a diuretic (in ESH 2009 7) is no longer recommended, particularly in case 
of a metabolic syndrome or risk of incident diabetes because of higher diabetogenic 
potential. In the recent guidelines, a combination of an ACE inhibitor and an ARB 
has become a non-preferred combination. On the other hand, according to recent 
guidelines, other drugs, such as aliskiren, has become accepted for combination 
antihypertensive treatment, especially in a multiple approach. 
 
There have been numerous studies in the course of the past couple of decades, which 
have lead to the combination medication recommended by these guidelines. The 
meta-analyses of Law et al. in 2003 6, and of Lindholm et al. 96, the ASCOT 31, 
ACCOMPLISH 66, ONTARGET 67, LIFE 58, ALPINE  63, FEVER  30, and CAFE 
trials 64, the meta-analyses of Bangalore et al. 102, and of Wald et al. 103,  Calhoun et 
al. 104,  Chapman et al. 105, and Musini et al. 106 are the most important ones (Table 
2). 
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2.3.2 Diabetic patients 
2.3.2.1 Initial antihypertensive medication 
 
Initial antihypertensive medication for diabetic patients, recommended by 12 
guidelines from 1994 to 2009, is described in Table 7.  
 
In 1994, the FHA working group guideline 32 recommended ACE inhibitors for 
initial antihypertensive medication, especially for diabetic nephropathy. With minor 
exceptions, since the late nineties, a blocker of renin-angiotensin system (whether an 
ACE inhibitor of an ARB), especially in case of diabetic nephropathy, has been the 
drug of choice for hypertensive diabetic patients. However, most of the trials before 
the early 2000s were carried out with ACE inhibitors, and therefore, due to lack of 
evidence supporting ARBs, ACE inhibitors were favored over ARBs in the JNC6 17, 
WHO-ISH 45, and BHS (1999) 51 guidelines. However, probably due to the 
UKPDS39 trial 8 and the SHEP trial 35, low-dose diuretics and BBs were also 
classified as possible treatments of choice for initial therapy in the guidelines of the 
late nineties.  CCBs and alpha-blockers were also stated as possible treatments of 
choice by the FHA working group guideline in 1994 32, and by the JNC6 17 in 1999.  
 
The FCCH guidelines (2002) 12 and (2005) 13, recommended all major 
antihypertensive agents, although RAS blockers were preferred in the case of 
diabetic nephropathy. The ESH guidelines (2003) 16 stated that all well tolerated and 
efficient agents can be used, although the ESH guidelines, also, favored ACE 
inhibitors for Type 1 diabetic nephropathy, and ARBs for Type 2 diabetic 
nephropathy. In fact, the ESH guidelines emphasized particularly the renoprotective 
effects of RAS blockers and stated that microalbuminuria in Type 1 or 2 diabetic 
patients is an indication for antihypertensive treatment, especially by RAS blockers, 
irrespective of the blood pressure values. The JNC7 18, in 2003, recommended BBs 
only in the case of concomitant ischaemic heart disease, whereas FCCH guidelines, 
(2005), noted that thiazide diuretics and BBs 107 without intrinsic sympathomimetic 
activity may increase blood glucose level but improve the diabetic patients 
prognosis 8. The BHS guidelines (2004) 52, besides favoring ACE inhibitors for 
Type 1 diabetic nephropathy and ARBs for Type 2 diabetic nephropathy, noted that 
BBs should be used with caution except with concomitant CHD.  
 
Since 2007, the guidelines have recommended RAS blockers as a compelling 
indication for diabetic patients. Still, all major agents were also indicated as options 
except BBs and thiazides in the ESH/ESC guidelines in 2007 19 and BBs (unless 
required for another reason) in the FCCH guidelines 14 in 2009. 
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Numerous studies have been leading the way for these recommendations during the 
past couple of decades. The meta-analysis of Pahor et al. 108, the STOP-2 trial 70, 
NORDIL 56, ABCD 38, ALLHAT  59 and CAPPP trials 55 have shown the benefits of 
different antihypertensive agents. The benefit of the ACE inhibitors and ARBs, as 
compared with placebo or other agents was shown in the ABCD 37, FACET 69, 
micro-HOPE 40, and LIFE trials 74. The studies of Lewis et al. 68, the IDNT 71, 
RENAAL 72, and IRMA-II trials 75 concerning the development and/or progression 
of diabetic nephropathy deserve also mentioning. A description of major clinical 
trials concerning hypertension and diabetes is shown in Table 3. 
 
2.3.2.2 Combination antihypertensive medication 
 
Combination antihypertensive medication for diabetic patients, recommended by 12 
guidelines from 1994 to 2009, is described in detail in Table 7.   
 
The FHA working group guidelines in 1994 32 recommended diuretics at low doses 
as a second line drug after initial therapy.  In the late nineties and early 2000s, an 
ACE inhibitor was favored over ARBs, as shown in the BHS guidelines (1999) 51 
and JNC7 18 (2003), although the ESH guidelines 16 (2003) stated that all well- 
tolerated and efficient agents are indicated. The FCCH guidelines (2002) 12 gave no 
specific recommendations separately for diabetic patients, concerning initial 
combination antihypertensive medication. Since the BHS guidelines 52 (2004), the 
golden standard and a compelling indication in the combination antihypertensive 
medication for diabetes is that a RAS blocker should be one of the partner drugs of 
antihypertensive treatment. However, the update of the FCCH guideline in 2005 13 
did not state RAS blockers as compelling indications for the initiation of 
combination antihypertensive medication for diabetic patients, although it noted the 
benefits of RAS blocker based medication. Similarly, for patients with essential 
hypertension, a combination of a diuretic and a BB was still one of the 
recommended two-drug combinations.    
 
Since 2007, guidelines have not recommended any combination of a diuretic 
(especially thiazide) and a BB in the treatment of diabetes unless a specific 
indication (for example concomitant CHD) exists.  
 
These recommendations favoring the use of RAS blockers are based on the LIFE 74, 
ADVANCE trial 78, and ACCOMPLISH trials 66. Accordingly, the UKPDS 8, LIFE 
74, and ASCOT trials 31 concerning the inferiority of BBs and diuretics, deserve to be 
pointed out. A description of major clinical trials concerning hypertension and 
diabetes is shown in Table 3. 
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After the publication of recent guidelines, there is evidence that no benefit is 
achieved if Aliskiren is added to standard therapy with renin-angiotensin system 
blockade for patients with Type 2 diabetes who are at high risk for cardiovascular 
and renal events 109.  
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2.3.3 Coronary heart disease patients 
2.3.3.1 Initial antihypertensive medication 
 
Initial antihypertensive medication for CHD patients, recommended by 12 
guidelines from 1994 to 2009, is described in Table 8.  
 
According to the Finnish national guidelines, 12, 13, 32, BB has been a drug of choice 
for the hypertensive CHD patients.  On the other hand, JNC6 17, BHS guidelines 
(1999) 51, JNC7 18, as well as the ESH guidelines (2003) 16, have recommended BBs 
to be used as primary drugs for hypertensive CHD patients in case of angina and/or 
after myocardial infarction. Their advantage was clearly shown in the meta-analysis 
of Freemantly et al. 110. The status of CCB has varied since the nineties, depending 
on which type of CCB is concerned, as shown in Table 8. Since JNC6 17, with an 
exception of BHS guidelines (1999) 51 and FCCH guidelines in 2002 12 and 2005 13, 
ACE inhibitors as antihypertensive drugs have been a compelling indication for 
CHD after MI. On the contrary, the FCCH guidelines in 2002 12 and 2005 13 did not 
recommend their use as compelling indications until in the most recent guidelines in 
2009 14. ARBs have become competitive drugs to ACE inhibitors since the 
ESH/ESC guidelines in 2007, although the FCCH guidelines in 2009 14 have 
recommended their use in case an ACE inhibitor is not tolerated.   
 
There have been numerous studies in the course of the past couple of decades, which 
have been leading the development of these guidelines. Furberg et al. 111 showed the 
disadvantage of short-acting CCBs in moderate to high doses, while Messerli et al. 
81 showed the benefit of verapamil and diltiazem. The JMIC-B showed no difference 
in the reduction of cardiac events and mortality with nifedipine as compared with 
ACE inhibitors. The meta-analysis of Al-Mallah et al. 112, which included 6 
randomized clinical trials: The HOPE 46, EUROPA 47, PEACE 50, QUIET 82, PART-
2 80, and CAMELOT 48 trials showed a modestly favorable effect of ACE inhibitors 
as compared with placebo, for CHD patients with preserved left ventricular function.  
The OPTIMAAL 83, VALIANT 85, and ONTARGET trials 67 (40% of CHD 
patients) have shown more or less similar benefits with ARBs as compared with 
ACE inhibitors. Neither the ALLHAT trial 59 (in which more than 50% had a history 
or signs of atherosclerotic cardiovascular disease) showed any significant difference 
in primary outcomes between the treatment with chlorthalidone, amlodipine, and 
lisinopril, although treatment with a thiazide-type diuretic was superior to an ACE 
inhibitor at preventing secondary outcomes. A description of major clinical trials 
concerning hypertension and CHD is shown in Table 4. 
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2.3.3.2 Combination antihypertensive medication 
 
Combination antihypertensive medication for CHD patients, recommended by 12 
guidelines from 1994 to 2009, is described in detail in Table 8.  
 
A limited number of guidelines have specified recommendations for combination 
antihypertensive medication for CHD patients, as shown in Table 8. Typical to these 
few specified recommendations (including the Finnish national guidelines 12, 14, 32) is 
that BB is the base of the treatment. Two of the most recent international guidelines 
7, 19 have stated that all major antihypertensives are acceptable for initiation of drug 
therapy as for CHD patients, although drugs in combination therapy were not 
specified. On the other hand, the FCCH guidelines in 2002 12 recommended a 
combination of a BB and a low-dose diuretic, whereas JNC7 18 mentioned that long-
acting dihydropyridine-CCBs are preferred for combination therapy with BBs. 
In the INVEST trial 84, a verapamil together with an ACE inhibitor-based treatment 
was clinically efficient as a BB plus a hydrochlorthiazide-based treatment. A 
description of major clinical trials concerning hypertension and CHD patients is 
shown in Table 4. 
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2.3.4 Uncomplicated hypertensive patients 
 
Antihypertensive medication for uncomplicated hypertensive patients, 
recommended by 12 guidelines from 1994 to 2009, is described in Table 9.  
 
As shown in Table 9, practically only the FCCH guidelines 12-14 and JNC6 17 have 
specified antihypertensive medication for uncomplicated hypertensive patients. In 
other guidelines, uncomplicated hypertensive patients have been included with 
patients with essential or primary hypertension, which is discussed in Chapter 2.3.1. 
 
The FCCH guidelines in 2002 12 recommended starting antihypertensive medication 
with low-dose thiazides, ACE inhibitors, or BBs. CCBs and ARBs were optional in 
specific cases. In 2005, the FCCH guidelines 13 stated that the treatment of 
uncomplicated hypertension can be initiated with RAS blockers, BBs, diuretics, and 
CCBs. However, they made a note on the poor evidence of benefits with BBs in the 
treatment of uncomplicated hypertension. In combination therapy, the FCCH 
guidelines in 2005 13 noted that most drugs can be combined. 
 
These recommendations are based on studies, most of which have been already 
mentioned in Chapter 2.3.1. In addition, the meta-analysis of Messerli et al. 1998 113 
concluded that BBs should no longer be considered appropriate first-line therapy of 
uncomplicated hypertension in elderly hypertensive patients whereas Messerli et al. 
2008 114 concluded that, in uncomplicated hypertension, neither diuretics nor BBs 
are acceptable for first-line treatment. 
 
According to the recently-published study of De Caterina et al. 115 (2010 after above 
guidelines), BBs should not be used as first choice for uncomplicated hypertension. 
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2.4 Prevalence of hypertension and control of BP in  
      population-based studies 
2.4.1 General population 
 
Numerous population-based studies have evaluated the prevalence of hypertension 
in general populations 3, 5, 116, 117. From the early eighties, the reported prevalence of 
hypertension has varied around the world, with the lowest prevalence in rural India 
(less than 10%) and the highest prevalence in Poland (approximately 70%) 3. From 
the early 1980s to the early 2000s, in economically developed countries, the 
prevalence of hypertension has ranged between approximately 20% and 50% at the 
140/90 mmHg threshold 3. In the mid-nineties, the age-standardized prevalence of 
hypertension in most populations has been less than 30% at the 160/95 mmHg 
threshold and less than 50% at the 140/90 mmHg threshold 5. 
 
The definition of hypertension has varied largely in epidemiological studies. 
Consequently, differences in hypertension criteria affect significantly the prevalence 
figures of hypertension, which requires to be taken into account. The definition of 
hypertension has commonly required a history of use of an antihypertensive agent 
and/or measurement of elevated BP, which most commonly has been ≥160/90 or 
≥140/90 mmHg.  
 
Control of BP has usually been reported among treated hypertensive patients. In 
numerous studies the control of hypertension has been reported among those who 
are aware of their hypertension and are being treated with antihypertensive 
medication. Levels of control among treated hypertensive patients have ranged from 
approximately 30% to 50% with a threshold value of 140/90 mmHg 3. 
  
Surveys have in several countries been repeated over time, or different surveys have 
been conducted at different points of time. For example, in the US, hypertension 
control among all patients, (BP less than 140/90 mmHg) improved from 27.3% in 
the period 1988-1994 to 50.1% in the years 2007-2008 117. The Monitoring Trends 
and Determinants in Cardiovascular Disease (MONICA) studies have been 
conducted in a number of European countries since the early 80s. In Finland as well 
as in most of the WHO MONICA populations, trends in prevalence, awareness, 
treatment, and control of hypertension has improved 5. However, the results obtained 
have varied considerably between different countries and regions 3, 116. There is 
evidence that, on the average, BP levels have been higher in European countries 
than in the US and Canada 116 (Figure 1). In the Finnish population, according to the 
FINRISK studies, BP values have decreased significantly during the past thirty years, 
some differences between sex and district of living, however, exists 2,  118. Altogether, 
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prevalence of hypertension and control of BP are still far from optimal 2,  118. In 1982, 
with a threshold value of 140/90 mmHg, prevalence of hypertension in Finland was 
on the average 59-68% for men and 40-55% for women. Of the hypertensive 
patients, 11-17% of men and 21-25% of women received antihypertensive drugs, 
and of those 12-15% of men and 10-15% of women had their BP controlled below 
140/90 mmHg.  In 2002, the corresponding figures were 48-52%, 26-32%, and 30-
35% for men, and 33-36%, 27-43%, and 22-36% for women, respectively 2,  118 
(Figure 2). In 2006, among Finnish primary care patients, roughly three-quarters of 
the hypertensive patients failed to reach the BP target of 140/90 mmHg 119. 
 
 
 
 
Figure 1. Hypertension Prevalence vs Stroke Mortality in 6 European and 2 North 
American Countries, Men and Women Combined (35-64 Years), Age-adjusted. Adapted 
from Wolf-Maier et al. 2003 116. 
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Figure 2. Prevalence, awareness, treatment and control of hypertension by sex in the 
national FINRISK study during 1982-2007. (Hypertension defined as systolic BP ≥ 140 
mmHg or diastolic BP ≥ 90 mmHg or antihypertensive drug treatment). Values of bars 
describe the mean, minimum, and maximum values. They are calculated from the 
average values from North Karelia, Northern Savo, and South-western Finland. Modified 
from Kastarinen et al. 2006  118 and Kastarinen e al. 2009 2. 
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2.4.2 Diabetic patients 
 
Hypertension is an extremely common co morbid condition in diabetes, affecting 
approximately 20-60% of diabetic patients 120. There is evidence that, control of 
hypertension is poorest for diabetic patients 121. However, there is also evidence that 
awareness, treatment, and control of hypertension has improved among the diabetic 
patients, although prevalence of hypertension has increased 122. Besides, Want et al. 
found no evidence of improvement for adults 20-44 years of age in US between 
1988 and 2008 122.  
 
Several population-based studies and/or otherwise representative studies (for 
example large database studies) have evaluated the prevalence of hypertension and 
control of BP among diabetic patients (Table 10). Like in the studies carried out for 
general populations, the definition of hypertension has varied largely in 
epidemiological studies. Differences in hypertension criteria affect significantly the 
prevalence figures of hypertension, as stated in the previous chapter. In these 
studies, the definition of hypertension has commonly required a history of use of an 
antihypertensive agent and/or  measurement of elevated BP, which in fact has varied 
greatly (being ≥130/80 mmHg at the lowest and ≥160/95 mmHg at the highest).  
 
As was done in the studies for general populations, the control of BP for diabetic 
patients was commonly evaluated among treated hypertensive patients. There are 
numerous studies in which the control of hypertension has been evaluated among 
those who are aware of their hypertension and are being treated with 
antihypertensive medication.  
 
As shown in Table 10, prevalence of hypertension and control of hypertension have 
varied greatly in different studies in the past 15-20 years. The great variation in 
these results can be partly explained by methodological differences. In Finland 
between 1972-1977, according to the framework of the North Karelia Project and 
the FINRISK study, the prevalence of hypertension (≥160/95 mmHg) in diabetic 
patients was 50.4% 123, while according to the FINRISK study in 1992, the 
prevalence of hypertension (≥140/90 mmHg) was 77% 124. 
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2.4.3 Coronary heart disease patients 
 
There are only a few population-based studies and/or otherwise valuable studies 
representing the whole population, which have evaluated cardiovascular risk factors, 
such as prevalence of hypertension and control of BP among CHD patients, as 
described in Table 11. Also for patients with CHD, the definition of hypertension 
has varied in epidemiological studies. Consequently, the difference in hypertension 
criteria affects significantly the obtained prevalence of hypertension, which requires 
to be taken into consideration. In these studies, hypertension has commonly been 
defined as “raised BP” i.e., systolic BP ≥140 mmHg and diastolic BP ≥90 mmHg. 
Alternatively, in some studies, hypertension has been defined by using the ESH/ESC 
2003 guidelines 16 i.e., systolic BP ≥140 mmHg (≥130 mmHg for diabetic patients) 
and diastolic BP ≥90 mmHg (≥80 mmHg for diabetic patients). Contrary to the 
studies made for general populations and for diabetic patients, control of BP of CHD 
patients has commonly been evaluated among all patients, not only among those 
with a history of hypertension.  However, in the Euroaspire Surveys I-III 148, 149, the 
control of hypertension has been assessed also among treated patients. Yet, all BP 
lowering drugs have not always necessarily been used for the treatment of 
hypertension.  
 
As shown in Table 11, prevalence of hypertension and control of hypertension have 
varied largely within different populations during the past 15 years. Despite a 
substantial increase in antihypertensive drug therapy in Euroaspire surveys I-III, 
control of BP remained unchanged at the level of 40% on the average in 8 European 
countries 148. The prevalence of hypertension in Euroaspire II 148, carried out in 
1999-2000, was slightly lower and therapeutic control of hypertension slightly 
higher in Finland than on the average in eight other European countries. In 
Euroaspire III 148, carried out in 2006-2007, the prevalence of hypertension was 
somewhat higher and control of hypertension somewhat lower in Finland than on the 
average in 8 European countries. 
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2.4.4 Uncomplicated hypertensive patients 
 
There are only a few population studies describing the prevalence and/or control of 
hypertension among uncomplicated hypertensive patients. However, practically all 
of these are limited to newly treated patients, patients of a certain age 156, or other 
subgroups, and do therefore not deserve further presentation in this context. 
 
2.5 Utilization of antihypertensive drugs in population-based  
      studies 
2.5.1 General population 
 
There is a huge number of studies dealing with representing antihypertensive 
treatment for general populations. The portion treated patients has commonly been 
reported as being hypertensive patients (i.e., treated hypertensive patients). 
However, the threshold BP for the classification of hypertension has been varying, 
which reflects to these percentages and requires to be taken into account.  
 
According to the WHO MONICA project in the late eighties and early nineties, 
using 140/90 mmHg for threshold, less than 30% of the hypertensive individuals 
were on antihypertensive medication in 20 out of 24 male populations, while less 
than 40% of the hypertensive individuals were on antihypertensive medication in 18 
out of 24 female populations 5. In Finland, in 1982, 1997, 2002, and 2007, using a 
140/90 mmHg threshold, 11-17%, 23-26%, 26-32%, and 26-38% of the 
hypertensive men were on antihypertensive drug treatment, respectively 2, 118. The 
corresponding figures for females were 20-25%, 23-33%, 27-43%, and 31-45%, 
respectively 2, 118 (Figure 2). In 1995, among Finnish primary health care patients, 
BBs were the drugs most frequently used by all patients. For women, combination 
therapy included more frequently diuretics, whereas ACE inhibitors were favored by 
men 157.  
 
The CardioMonitor 2004 Survey in 5 western European countries and in the United 
States has shown that the use of thiazides was quite similar across these countries 
(29-31%) 158. In contrast, the use of other antihypertensive drug classes varied 
considerably from one country to another, especially for BBs (20-49%), ACE 
inhibitors (27-52%), and ARBs (18-36%). The use of combination drug therapy was 
highest in the US (64% vs. 44-59% across the European countries) 158. The I-
SEARCH study between 2005 and 2006 in 26 countries showed that, in the overall 
population, of those on antihypertensive medication, approximately 30% used one 
drug, approximately 40% used two drugs, and approximately 30% used 3 or more 
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antihypertensive drugs 159. According to the I-SEARCH study, in monotherapy, 
ACE inhibitors were most frequently used by men (29.8% vs. 26.3%), while BBs 
were most frequently used by women (27.6% vs. 24.2%) 159. 
 
In a study of three similar population-based databases of dispensed drugs for newly 
treated hypertensive patients, carried out in 2006 in Italy, Sweden, and Netherlands, 
ACE inhibitors were used as first-line agent by 23%, 21%, and 13%, in above order. 
Corresponding figures concerning BBs were 18%, 33%, and 34%, respectively 160.  
 
2.5.2 Diabetic patients 
 
There are several population-based studies and/or otherwise representative national 
studies treating utilization of antihypertensive drugs for diabetic patients (Table 12). 
There are methodological differences in these studies and therefore the results are 
not equally comparable with each other. Despite the methodological differences, the 
distribution of major antihypertensive agents differs between the populations. 
Nevertheless, it seems that utilization of antihypertensive drugs for diabetic patients 
has increased during the past few decades. In addition, combination therapy seems 
to have increased. Yet there is still some way to go for better management of 
hypertension. On the other hand, longitudinal studies carried out 1993-2001 in UK 
128, 1993-2001 in Canada 161, and 1997-2003 in Taiwan 162, demonstrate that the 
earlier the study was carried out, the less RAS blockers were used. It seems that both 
in cross-sectional and in longitudinal studies, BBs were clearly less frequently used 
than RAS blockers. This trend is very distinctly seen in longitudinal study in 
Taiwan, carried out from 1997 to 2003 162.  
 
In the primary care setting in Finland from 1992 to 1994, ACE inhibitors, BBs, 
CCBs, and diuretics were used by 46%, 39%, 31%, and 31%, of the hypertensive 
patients, respectively. Sixty-one percent of the hypertensive diabetic patients were 
on monotherapy and 8% had three or more antihypertensive drugs 163. 
 
2.5.2.1 Monotherapy 
 
There are not many studies describing the utilization of antihypertensive agents in 
monotherapy (Table 13). Some methodological differences exist in these studies, 
and the results are therefore not equally comparable with each other. ARBs were 
used on the average by 22-60%, while BBs were used, respectively, by 8-35%. 
There seems to be an increasing trend in the use of ARBs also in monotherapy 
(Table 13).  
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2.5.2.2 Combination therapy 
 
Only a few representative studies concern combination antihypertensive treatment 
for diabetic patients. The most frequent combination therapy in Alberta (province of 
Canada) in 2000 was an ACE inhibitor plus a CCB (26% of 2-drug combinations) 
followed by an ACE plus a loop diuretic (14% of 2-drug combinations) 137. In the 
UK, from 1993 to 2001, (within the first year entering the study) the most frequently 
used 2-drug combination was a RAS blocker plus a CCB (23% of 2-drug 
combinations) while the most frequently used 3-drug combination was a 
combination of a RAS blocker, a CCB, and a diuretic (38% of 3-drug combinations) 
128.  In Taiwan, from 1997 to 2000, the most frequently used 2-drug combination 
was a RAS blocker plus a CCB (23%, 31%, and 38% of 2-drug combinations in 
1997, 2000, and 2003, respectively) while the 3-drug combination most frequently 
used was a combination of RAS blocker(s), BB(s), and CCB(s) (17%, 29%, and 
33% of triple therapies in 1997, 2000, and 2003, respectively) 162. 
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2.5.3 Coronary heart disease patients 
 
There are several papers treating the utilization of antihypertensive drugs in 
population-based studies and/or otherwise representative national studies of CHD 
patients (Table 14). Because of methodological differences in these studies, the 
results are not equally comparable with each other.  
On the other hand, the longitudinal Euroaspire Surveys I,II, and III, 148, 149, 152, 153, 
carried out in several European countries (including Finland), give an opportunity to 
compare the results with each other. In addition, trends in antihypertensive 
medication among CHD patients since mid-nineties will be uncovered. In studies 
concerning CHD patients, such as the Euroaspire Surveys, BP-lowering drugs (for 
instance BBs and ACE inhibitors) may not have always been prescribed for the 
treatment of hypertension. Nevertheless, it seems that utilization of BP lowering 
drugs for CHD patients has increased during the past 15-20 years. Utilization of BBs 
and diuretics and, particularly, RAS blockers, has increased widely. However, there 
are differences between the countries (Table 14). According to Euroaspire Surveys 
I-III, BBs are used more and diuretics and RAS blockers less in Finland than in the 
Czech Republic, France, Germany, Hungary, Italy, Netherlands, and Slovenia 149. 
 
2.5.4 Uncomplicated hypertensive patients 
 
Some studies describe the utilization of antihypertensive drugs in population-based 
studies of uncomplicated hypertensive patients. Practically all of these are limited to 
newly treated patients, elderly patients or other subgroups, and therefore only a 
retrospective prescription-based survey in Bahrain in 1998-2000 deserves 
mentioning 167.  Therein, in 1998, BBs were used by 65%, ACE inhibitors by 21%, 
CCBs by 20%, and diuretics by 27% while the corresponding figures in 2000 were 
60%, 27%, 24%, and 27%, respectively 167. 
 
Table 13. Monotherapy according to earlier population-based studies of diabetic patients
Monotherapy Year(s) BB(%) CCB(%) D(%) ACE(%) ARB(%) ACE/ARB(%) Alpha Other
Gulliford et al. (128) 93-01 34.7 13.0 17.4 NR NR 34.7 NR NR
Johnson et al. (139) 98-01 11.5 11.2  9.4 NR NR  59.5 6.6 1.7
Supina et al. (137) 2000 8 13 6 NR NR 74 NR NR
Chiang et al. (162) 1997 18.2 44.4 6.6 NR NR 22.0 NR 8.9
     — ⁄ ⁄ — 2000 14.5 36.3 4.8 NR NR 39.0 NR 5.4
     — ⁄ ⁄ — 2003 11.7 36.6 3.7 NR NR 44.8 NR 3.2
BB, beta-blocker; CCB, calcium channel blocker; D, diuretic; ACE, Angiotensin converting enzyme inhibitor;
NR, not reported; ARB, angiotensin receptor blocker; alpha, alpha-blocker.
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3 Aims of the Study 
 
 
The purpose of this study was to evaluate the rationality of antihypertensive drug 
treatment in Finland between 2000 and 2006 in accordance with treatment 
guidelines.  The specific aims were: 
 
1. To assess utilization of antihypertensive drug therapy and control of 
hypertension among Finnish adult diabetic patients (I). 
 
2. To assess utilization of antihypertensive drug therapy and control of 
hypertension among Finnish adult coronary heart disease (CHD) patients 
(II). 
 
3. To assess utilization of antihypertensive drug therapy and control of 
hypertension among Finnish adult uncomplicated hypertensive patients 
(III). 
 
4. To calculate the expected improvements in the control of hypertension and 
the expected reductions in cardiovascular morbidity, with intensified 
antihypertensive treatment (III). 
 
5. To assess changes in the utilization of antihypertensive medication for 
subjects treated for moderate to severe hypertension and uncomplicated 
mild hypertension, in relation with changes in concomitant disease profiles 
(IV). 
 
6. To assess whether utilization of antihypertensive drugs in late 2006 differs 
between recently treated and formerly treated moderately to severely 
hypertensive patients (IV). 
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4 Materials and Methods 
4.1 Study designs and populations 
 
Studies I-III 
Two different data, the data of the Health 2000 Survey (H2000)) and the database of 
the Social Insurance Institution (SII), partly in parallel and partly complementary to 
each other, were used to assess changes in the utilization of antihypertensive drugs 
from 2000 to 2006 among Finnish adult patients with diabetes (I), CHD (II), and 
uncomplicated hypertension (III), and to evaluate the treatment and control of 
hypertension in these 3 subgroups. In addition, data of the Health 2000 survey were 
used to crossvalidate drug utilization data obtained from the database of the SII, and 
vice versa. 
 
Study III 
Among uncomplicated hypertensive patients, data of the Health 2000 survey and the 
database of the SII were used to calculate the achievable reduction in BP and 
cardiovascular morbidity, with intensified antihypertensive treatment. 
 
Study IV 
The database of SII was used to disclose changes in the utilization of 
antihypertensive drugs in subjects treated for moderate to severe hypertension and 
mild uncomplicated hypertension, in relation with changes in concomitant disease 
profiles between 2000 and 2006, and to assess whether utilization of 
antihypertensive drugs in late 2006 differs between recently treated and formerly 
treated moderately to severely hypertensive patients (IV).  
 
4.1.1 The Health 2000 Survey 
 
The Health 2000 Survey was carried out in Finland from late 2000 to early 2001. 
The population of the study was a two-stage stratified cluster sample representing 
the whole Finnish population aged 30 years or over. The frame was regionally 
stratified according to the five university hospital districts, each containing 
approximately one million inhabitants. From these, 16 health care districts were 
sampled as clusters. Firstly, the 15 largest cities were included with the probability 
of one. Secondly, the remaining 65 health care districts were selected by applying 
the systematic probability proportional to size method. Finally, from these 80 
clusters, a sample of 8028 persons was selected by systematic sampling (Figure 3).  
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Figure 3. Study areas of the Health 2000 Survey. Study locations of the Health 2000 
Survey are marked in dark grey on the map of Finland.  
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The Health 2000 Survey included a structured health interview. The health interview 
elicited information about the participants’ health, illnesses, medication, and 
functional ability as well as sociodemographic and health behavioral factors. In 
addition, during the health interview, the participant was given a questionnaire, 
which was to be returned on arrival at the health examination. If the person did not 
participate in the main interview, a supplementary interview was conducted later or 
eventually a questionnaire was sent. The participation rate in the health interview 
was 87% (n = 6 986). The participants took part at a comprehensive health 
examination in a health center (n= 6 354, 79% of the sample). The examination 
included measurement of anthropometry, functional capacity, and laboratory tests. 
In addition, a physical examination performed by centrally trained physicians and 
nurses was completed. The participants’ height, weight, waist, and clinic BP were 
measured. Fasting blood samples for serum glucose and lipids were taken. In 
addition, a 12-lead resting ECG was recorded. An abbreviated health examination 
was conducted at home or in an institution for those who did not participate in the 
study center examination (n = 417, 5% of the sample). A detailed description of the 
study design, data collection methods, and health and functional status of population 
of the study have been published elsewhere 168, 169.  
 
The study protocol of the Health 2000 Survey was approved by the Epidemiology 
Ethics Committee of the Helsinki and Uusimaa hospital region, and all participants 
gave a signed informed consent. 
 
The study cohort from the initial Health 2000 Survey for studies I-III was selected as 
follows. 
Persons who had not participated in the health examination (n=1257), had 
incomplete laboratory data (n=81), had not completed questionnaires properly 
(n=360), or had not participated in two measurements of BP (n=121), were excluded 
from the study. Altogether 6209 subjects were included for further analyses. 
 
Study I  
Of those 6209 subjects, 388 patients with diabetes were included to Study I. Of these 
324 were hypertensives, and 227 of the hypertensive diabetic patients used 
antihypertensive drugs. See Article I, Figure 1. 
 
Study II 
Of those 6209 subjects, 527 coronary heart disease patients were included to Study 
II. Of these 396 were hypertensives, and 345 of the hypertensive CHD patients used 
antihypertensive drugs. See Article II, Figure 1. 
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Study III 
Of those 6209 subjects, 1416 were using antihypertensive medication. Of those 
using antihypertensive medication, 687 subjects with diabetes, CHD, cardiac 
arrhythmias, or chronic heart failure were excluded. The remaining 729 
uncomplicated hypertensive patients were included to Study III. See Article III, 
Figure 1. 
 
4.1.2 Database of the Social Insurance Institution 
 
Studies I-II 
From the database of SII of Finland, comprehensive information on all prescribed 
antihypertensive and lipid-lowering drugs purchased in Finland between September 
1st and November 30th in 2000, and in 2006, respectively, was gathered. Thereby 
prescribed drugs purchased by 722 405 individuals in 2000, and 993 680 in 2006, 
respectively, were included. Patients under 30 years were not included. 
 
Study I 
The data including antihypertensive- and lipid-lowering drug prescriptions were 
linked to the records concerning the patients entitled to reimbursed antidiabetic 
medication costs during the same year or one year after, respectively. Thereby, all 
Finnish adult diabetic patients aged 30 years or more, with entitlement to 
reimbursements for diabetes medication costs, were identified and included to the 
study (143 366 subjects in 2000-2001 and 187 099 subjects in 2006-2007). In 
addition, the entitlement to reimbursements for hypertension and/or CHD 
medication costs was also taken into account when applicable. See Article I, Figure 
1. 
 
Study II 
The data including antihypertensive and lipid-lowering drug prescriptions, 
accordingly, were linked to the records concerning the patients entitled to 
reimbursement for CHD medication costs during the respective year. Consequently, 
all Finnish adult subjects aged 30 years or more with entitlement to reimbursement 
for CHD medication costs were identified and included to the study (192 440 
subjects in 2000 and 206 394 subjects in 2006). In addition, the entitlement to 
reimbursements for hypertension and/or diabetes medication costs was also taken 
into account when applicable. See Article II, Figure 1. 
 
Study III 
From the database of SII of Finland, 100% of the prescribed antihypertensive drugs 
purchased in Finland between September 1st and November 30th in 2000, and in 
2006, respectively, were collected. Patients under 30 years of age were excluded. 
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Thereby 699 936 individuals aged 30 years or over in 2000, and 880 654 in 2006, 
who used antihypertensive drugs, were identified and included to the study. From 
these 240 950 subjects with diabetes, CHD, cardiac arrhythmias, or CHF in 2000, 
and 289 448 in 2006, were excluded, and from the remaining subjects 428 986 
treated uncomplicated hypertensive subjects were identified in 2000 and 591 206 in 
2006. Of these, 264 313 moderately to severely hypertensive patients in 2000 and 
288 352 in 2006 were identified. Accordingly, 164 673 mildly hypertensive patients 
in 2000, and 302 854 in 2006, respectively, were identified. See Article III, Figure 1. 
 
Study IV 
From the database of SII of Finland, 100% of the prescribed antihypertensive drugs 
purchased in Finland between September 1st and November 30th in 2000, and in 
2006, respectively, were collected. These data were linked to the records of the 
subjects who were entitled to reimbursement of the medication costs of hypertension, 
diabetes, coronary heart disease (CHD), chronic heart failure (CHF), and cardiac 
arrhytmias, in 2000 and in 2006, respectively. In addition, records concerning 
reimbursements of antidiabetic medication costs, also one year after (i.e., 2001 and 
2007, respectively), were included to the study. Patients under 30 years were not 
included. Consequently, from these data 274 791 formerly diagnosed moderately to 
severely hypertensives, 70 185 patients with uncomplicated mild hypertension, and 
91 843 recently diagnosed moderately to severely hypertensives were identified.  
 
4.2 Drug therapy 
 
In the Health 2000 Survey, information on medication was elicited from a home 
interview and questionnaires were completed by centrally trained interviewers, 
described in detail elsewhere 168, 169. The database of SII, included practically 100% 
of the prescriptions on antihypertensive and lipid-lowering drugs purchased by the 
Finnish population between 1st September and 30th November in 2000, and in 2006, 
respectively. All purchased drugs have been considered as a drugs used regularly. If 
a combination drug product was taken, the drug was accounted for in both drug 
classes. 
 
4.3 Blood pressure measurement 
 
BP measurements were available only in the Health 2000 Survey. BP was measured 
with the patient in a sitting position, from the right arm after a minimum of 10 
minutes rest, with a conventional, calibrated sphygmomanometer (Mercuro 300, 
Speidel & Keller, Jungingen, Germany), by centrally trained professionals. The 
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subjects were given instructions on how to prepare for the measurement. The 
measurement was done using a pressure cuff of appropriate size and methods in 
accordance with current guidelines 170. The width of the rubber cuff was 12 cm and 
its length, 35 cm. If the proximal circumference of the upper arm measured at a 
height of 5 cm from the crook of the arm was in excess of 35 cm, a larger cuff 
(width 15, length 43 cm) was used. Systolic BP and diastolic BP were defined 
according to Korotkoff sounds I and V. The mean values of two measurements taken 
with a two-minute interval determined the systolic and diastolic BP.   
 
4.4 Laboratory analyses 
 
Laboratory analyses were available only in the Health 2000 Survey. Venous blood 
samples were taken from the antecubital vein after a minimum of four hours fasting. 
Total cholesterol, low density lipoprotein (LDL)-cholesterol, high density 
lipoprotein (HDL)-cholesterol, as well as the triglyceride and glucose concentrations 
were determined enzymatically (Roche Diagnostic, Mannheim, Germany, for HDL 
and LDL-cholesterol; Olympus System Reagent, Hamburg, for total cholesterol, 
triglyceride, and glucose) with a clinical chemistry analyzer (Olympus, AU4000, 
Hamburg, Germany). 
 
4.5 Electrocardiography 
 
ECGs, which were utilized in the diagnosis of MI and CHD, were available only in 
the Health 2000 Survey. Standard resting 12-lead ECG recordings were carried out 
in accordance with general clinical recommendations 170, 171. ECGs were digitally 
recorded with a Marquette MAC 5000 device. The speed of paper during the 
recordings was 50mm per second. The ECGs were stored as digital data on a 
Marquette MUSE CV 5B system (Marquette Hellige, Milwaukee, WI, USA). All 
ECGs were overread by a single physician experienced with electrocardiography.  
 
4.6 Medical history 
 
In the Health 2000 survey, information concerning the subjects’ medical history was 
elicited from health interviews, questionnaires, comprehensive health examinations 
(including clinical examination and laboratory analyses) of the initial Health 2000 
Survey (I-III). In the database of SII, the information concerning medical history 
was simply based on subjects’ entitlement to drug reimbursements for the 
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medication costs of hypertension, diabetes, CHD, CHF, and cardiac arrhythmias (I-
IV).  
 
4.7 Definitions 
4.7.1 The Health 2000 Survey 
 
Studies I-III 
A hypertensive patient was defined as being subject to at least one of  four 
conditions: 1. documented definite hypertension diagnosis made by a physician at 
the health examination; 2. entitlement to reimbursements of hypertension medication 
costs; 3. a BP of 140/90 mmHg or over as measured at the health examination of the 
Health 2000 Survey; 4.  a self-reported history of physician-diagnosed hypertension 
together with a regular use of antihypertensive medication (in Study II) or if he or 
she was taking antihypertensive medication (in Study I). All oral BBs, diuretics, 
antiadrenergic drugs, CCBs, ACE inhibitors, and ARBs were defined as 
antihypertensive regimens.  
Diabetes mellitus was defined as a fasting serum glucose level of at least 7.0 mmol/l 
and/or a history of the use of antidiabetic drugs. The definition of CHD required at 
least one of the following: diagnosis of myocardial infarction (MI) and/or angina 
pectoris during the field examination; large Q-waves in ECG (including Minnesota 
codes 1.1 or 1.2 together with 5.1-2); hospitalization for CHD, a history of a 
coronary revascularization procedure; or having the entitlement to reimbursement 
for CHD medication costs. Chronic heart failure was defined by a documented 
history of congestive heart failure or a positive response to the medication for CHF. 
Cardiac arrhythmias were defined by a documented history of undeniable cardiac 
arrhythmia, existence of a cardiac pacemaker, or entitlement to reimbursement of 
cardiac arrhythmias medication costs conceded by SII. Definition of MI required 
either a clinical diagnosis of MI by the examining physician, large Q-waves 
indicating probable earlier MI (including Minnesota codes 1.1 or 1.2 together with 
5.1-2), or an earlier hospital discharge with a diagnosis of MI (ICD-8 or ICD-9 code 
410 or ICD-10 codes I21-I22). Peripheral arterial disease was defined by a 
documented history of arteriosclerosis of lower extremities or typical symptoms of 
claudication. Cerebrovascular disease was defined by a documented history of 
ischaemic or hemorrhagic stroke, transient ischaemic attack (TIA), or an 
anamnestically reliable stroke confirmed by a physician at the health examination. 
Retinopathy was defined as an earlier physician-made diagnosis of diabetic 
retinopathy, and nephropathy, as an earlier diagnosed renal failure, albuminuria, or 
changes in renal function caused by diabetes.  
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The definition of dyslipidemia was based on the Finnish dyslipidemia guidelines and 
required at least one of the following: A serum LDL-cholesterol value over 3.0 
mmol/l; a serum triglyceride value over 2.0 mmol/l; serum HDL-cholesterol value 
less than 1.0 mmol/l; or the individual was already under lipid-lowering medication. 
As lipid-lowering drugs we included all drugs lowering serum cholesterol and 
triglycerides (fibrates also included). Smoking was defined as daily use of tobacco. 
 
Study III 
The definition of uncomplicated hypertension required a regular use of 
antihypertensive medication without presence of diabetes, CHD, cardiac arrhythmias, 
or CHF. The definition of mild hypertension required regular use of antihypertensive 
medication without entitlement to reimbursement for hypertension medication costs 
conceded by SII. The definition of moderate to severe hypertension required regular 
use of antihypertensive medication with entitlement to reimbursement for 
hypertension medication costs conceded by SII. 
 
4.7.2 Database of the Social Insurance Institution 
 
Studies I-IV 
Hypertension, CHD, cardiac arrhythmias, and CHF, were defined as cases entitling 
to reimbursement for the medication costs of these specific illnesses as conceded by 
SII in 2000 and 2006, respectively. In case of diabetes, until 2010, the entitlement to 
reimbursement for diabetes medication costs may not have been conceded earlier 
than 6 months from the diagnosis of diabetes. Therefore, diabetic patients were 
defined as those entitled to reimbursement for antidiabetic medication costs during 
2000 or 2001, and 2006 or 2007, respectively. Subjects using antihypertensive 
medication were defined as those who had purchased prescribed BP-lowering 
medication (oral BBs, diuretics, antiadrenergic drugs, CCBs, ACE inhibitors, or 
ARBs) between September 1st and November 30th in 2000, or 2006, respectively. 
 
Study III 
Those who had purchased BP-lowering drugs and were not entitled to 
reimbursement for medication costs of CHD, cardiac arrhythmias, CHF, or diabetes, 
were determined as uncomplicated hypertensive subjects. Accordingly, of those 
uncomplicated hypertensives, subjects were defined as moderately to severely 
hypertensive patients if they were entitled to reimbursement for hypertension 
medication costs, and, as mildly hypertensive patients, if they were not entitled to 
such reimbursement. 
 
Study IV 
Those using antihypertensive drugs without reimbursement for medication costs of 
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hypertension, diabetes, CHD, CHF, or cardiac arrhythmias, were determined as 
uncomplicated mild hypertensives. As moderately to severely hypertensive subjects 
were defined those who were entitled to reimbursement for hypertension medication 
costs and who had purchased antihypertensive drugs. Though, subjects who were 
entitled to reimbursement for hypertension medication costs in 2006 but not in 2000 
and who had purchased antihypertensive drugs in 2006 but not in 2000 were 
determined as recently diagnosed moderately to severely hypertensive subjects. On 
the other hand, those subjects who were entitled to reimbursement for hypertension 
medication costs in both 2000 and 2006 and who had purchased antihypertensive 
drug both in 2000 and 2006, were determined as formerly diagnosed moderately to 
severely hypertensive subjects. 
 
4.8 Control of hypertension and estimated reduction of BP  
      and cardiovascular morbidity 
 
BP levels were measured only at the Health 2000 Survey in the beginning of the 
2000s. BP levels and control of hypertension in 2006 were calculated by linking the 
data of the Health 2000 Survey  and the database data of SII together and taking into 
account changes in age, sex, and drug utilization (mean number of antihypertensive 
drugs per treated subject) of the target population between late 2000 and late 2006. 
In addition, BP reductions as well as relative risks of stroke and ischaemic heart 
disease (IHD) events were calculated in resemblance with Law’s meta-analyses 95, 
taking into account pre-treatment systolic and diastolic BP, age, number of drugs, 
and dose. The treatment was intensified, in theory, by adding one to two half 
standard doses (or one to two standard doses accordingly) only for those with a BP 
≥140/90 mmHg. No drugs were added if a BP was already below 140/90 mmHg. 
The second drug was added only if the control of hypertension (BP<140/90 mmHg) 
was not achieved with the first drug add-on therapy. 
 
4.9 Statistical analyses 
 
Statistical analyses were performed with a SAS software version 9.1, (SAS Institute, 
Cary, North Carolina, USA). In studies I-III concerning data of the Health 2000 
Survey, population weighting was taken into account. In studies I-III, comparisons 
between the Health 2000 Survey and the database of SII were made using a one-
group t-test where the database mean value was taken as a constant. Categorical 
variables were compared with a chi-squared test where the database data was used to 
calculate the expected frequencies. The data from the databases of SII represent the 
whole population. Therefore, no statistical methods were used when comparing the 
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database data. Data in tables are reported as mean values (SD) and/or percentages (I-
IV). A P value of less than 0.05 was considered statistically significant.  
 
Study I 
A logistic regression analysis was used to calculate univariate odd ratios for a 
potential determinant of better controlled hypertension (BP less than 140/90 mmHg). 
Multivariate logistic regression with backward selection was used to identify 
independent determinants of a BP less than 140/90 mmHg. The variables included in 
the multivariate analyses were those reaching statistical significance in the 
univariate analyses. Only significant variables were retained in the model.  
 
Study III 
BP reductions as well as relative risks of stroke and ischaemic heart disease (IHD) 
events were calculated in resemblance with Law’s meta-analyses, recently published 
and described in detail elsewhere 95, taking into account pre-treatment systolic and 
diastolic BP, age, number of drugs, and dose. The estimated effect of one drug at 
standard dosage at lowering BP from a pre-treatment blood pressure P is therefore  
(9.1 + 0.10 (P-154)) for systolic BP and (5.5 + 0.11 (P-97)) for diastolic BP. So, for 
example, the reduction in systolic BP was 8.7 mmHg from a pre-treatment value of 
150 mmHg, and 4.7 mmHg in diastolic BP, from a pretreatment value of 90 mmHg. 
The higher the pre-treatment BP value was, the higher was the decrease in BP, and 
vice versa. The estimated BP reduction for two or three drugs at standard dosages 
was calculated by applying these equations to each drug in turn, allowing for the 
effect of the first in lowering pre-treatment BP for the second, and the second for the 
third.    
 
In addition, the BP reductions obtained from one, two, and three drugs at half 
standard dose were [R + n x 0.078(P-150)] for systolic BP and [R + n x 0.088(P-90)] 
for diastolic BP, whereas P is the pre-treatment BP. R for systolic BP is 6.7 for the 
first drug, 13.3 for the second drug, and 19.9 for the third. For diastolic BP, 
accordingly, R is 3.7 for the first drug, 7.3 for the second drug, and 10.7 for the third 
drug. Thereby the first half standard dose decreases BP 6.7/3.7 mmHg, the second, 
13.3/7.3 mmHg, and the third, 19.9/10.7 mmHg, when the pre-treatment BP is 
150/90 mmHg. The higher the pre-treatment BP value is, the higher is the decrease 
in BP, and vice versa.  
 
The associations between systolic and diastolic BP and CHD events and stroke were 
taken, as in Law’s meta-analysis 95, from the largest published meta-analysis of 61 
cohort studies 23. Age-specific slopes of the lines (regression coefficients) were 
published, permitting the calculation of the predicted proportional reduction in 
disease events for any age and BP difference. For an age-specific regression slope S, 
and decrease in BP d, the relative risk was calculated using the formula  
Materials and Methods 
 
THL — Research 103, 2013 72 Antihypertensive Drug Therapy in Finland 
 
Sd/20 for systolic BP and Sd/10 for diastolic BP. Of these, the average value was 
used for relative risk.   
 
Study IV 
Also two separate groups of patients were compared. Because of their differences in 
the mean values of their age, distribution of gender, and the geographical district of 
living, the prevalence of clinical diagnosis and the utilization of drugs were adjusted 
for age, gender, and district of living.  
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5 Results 
5.1 Characteristics of study population 
5.1.1 Study I (Diabetic patients) 
 
The mean age of the diabetic patients in the Health 2000 Survey was 63 years, and 
56% of them were males. Eighty-five percent of the diabetic patients had Type 2 
diabetes. The mean BP was 147/83 mmHg, and 83% were receiving 
antihypertensive drugs. Twenty-one percent had CHD, 9% had suffered myocardial 
infarction, and 19% were current smokers. Diabetic patients in the database of SII, 
were on the average 2 years older, and the prevalence of females was somewhat 
higher than in the Health 2000 Survey. However, among the diabetic patients 
receiving antihypertensive drugs, there were neither age nor sex differences between 
the results of the Health 2000 Survey and the database of SII. Characteristics of the 
Finnish adult diabetic patients are shown in detail in Article I, Table 1.  
 
5.1.2 Study II (CHD patients) 
 
The mean age of the CHD patients in the Health 2000 Survey was 70 years, and 
55% of them were males. The mean BP was 145/80 mmHg, and 82% were receiving 
BP-lowering drugs. Twenty-seven percent of the patients had gone through a 
coronary revascularization (PCTA or CABG). Seventeen percent of the patients had 
diabetes, 37% of the patients had suffered myocardial infarction, and 11% were 
currently smokers. There were no statistically significant differences in 
characteristics of the CHD patients between the Health 2000 Survey and the 
database of SII. Characteristics of the Finnish adult CHD patients are shown in 
detail in Article II, Table 1.  
 
5.1.3 Study III (Uncomplicated hypertensive patients) 
 
The mean age of the uncomplicated hypertensive patients in the Health 2000 Survey 
was 60 years, and 63% of them were females. The mean BP was 146/87 mmHg, and 
the mean duration of hypertension had been 12 years. Fifteen percent of the patients 
were currently smokers. Uncomplicated hypertensive patients in the database of SII 
were on the average 2 years older, and they used slightly more diuretics than their 
counterparts in the Health 2000 Survey. 
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Characteristics of the Finnish adult uncomplicated hypertensive patients are shown 
in detail in Article III, Table 1. 
 
5.1.4 Study IV 
5.1.4.1 Subjects with uncomplicated mild hypertension 
 
The mean age of the subjects with uncomplicated mild hypertension in the database 
of SII in 2000 was 60 years (66 years in 2006), and 70% of them were females.  	  
5.1.4.2 Subjects with moderate to severe hypertension 
 
The mean age of the subjects with moderate to severe hypertension in the database 
of SII in 2000 was 63 years (69 years in 2006), and 58% of them were females. 
Thirteen percent of the patients had diabetes, 13% had CHD, 4% had CHF, and 
2.5% had cardiac arrhythmias.  
 
5.1.4.3 Formerly diagnosed moderately to severely hypertensive subjects 
 
The mean age of the subjects with formerly diagnosed moderate to severe 
hypertension in the database of SII in 2006 was 69 years, and 58% of them were 
females. Twenty-one percent of the patients had diabetes, 17% had CHD, 5% had 
CHF, and 2.8% had cardiac arrhythmias. 
 
5.1.4.4 Recently diagnosed moderately to severely hypertensive subjects 
 
The mean age of the subjects with recently diagnosed moderate to severe 
hypertension in the database of SII in 2006 was 65.3 years, and 53% of them were 
females. Twenty-one percent of the patients had diabetes, 17% had CHD, 5% had 
CHF, and 3.5% had cardiac arrhythmias.  
 
5.2 Prevalence, treatment, and control of hypertension (I-III) 
5.2.1 The Health 2000 Survey 
 
In the beginning of the 2000s, 83% of the diabetic patients were hypertensive and 
69% of them were using BP-lowering medication. Accordingly, 75% of the CHD 
patients were hypertensives and 88% of them were using BP-lowering medication. 
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Of all hypertensive diabetic patients receiving BP-lowering drugs, 31% had a BP 
less than 140/90 mmHg, and 14%, less than 130/80 mmHg. Of all hypertensive 
CHD patients receiving BP-lowering drugs, the respective figures were 25% and 9%. 
Among uncomplicated hypertensive patients, 30% of those treated for hypertension 
had their BP controlled down below 140/90 mmHg. The control of BP according to 
the number of BP-lowering drugs among hypertensive diabetic patients receiving 
BP-lowering drugs is shown in Figure 2.  Among diabetic patients, better control of 
hypertension was associated with lower pulse pressure and lower mean arterial 
pressure. If pulse pressure and mean arterial pressure were excluded from the 
analysis, only CHF was independently associated with better control of hypertension. 
Among the CHD patients, a BP level of less than 140/90 mmHg tended to be 
reached more often in younger (≤ 70 years of age) than in older patients (30 vs. 21%, 
P= 0.06). 
 
 
POOR CONTROL OF BLOOD PRESSURE  
(independent of the number of antihypertensive drugs used) 
 
 
 
 
Figure 4. Association between control of blood pressure and number of antihypertensive 
drugs with different blood pressure cut of point. Only hypertensive diabetic patients 
(n=227) receiving antihypertensive drugs included. Results between patients using 1, 2, 
or ≥3 drugs are not comparable with each other because the characteristics of these 
patients are not equal. Adapted from Ahola et al. J Hypertens 2009, 27:2283-2293 (I). 
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5.2.2 Database of the Social Insurance Institution 
 
The number of diabetic patients receiving antihypertensive drugs increased by 53% 
(from 80 478 to 123 176) from 2000 to 2006. Accordingly, the number of CHD 
patients receiving BP-lowering drugs increased by 13% (from 141 454 to 160 262). 
The number of uncomplicated hypertensive patients receiving antihypertensive 
drugs increased by 38% (from 428 986 to 591 206), although the number of treated 
mildly hypertensives increased by 84% (from 164 673 to 302 854), respectively, 
from 2000 and 2006.  
 
5.3 Estimated control of hypertension and reduction of BP and  
      cardiovascular morbidity, with intensified antihypertensive  
      treatment, among uncomplicated hypertensive subjects (III) 
 
Taking into account changes in age, sex, and the mean number of antihypertensive 
drugs of the target population between 2000 and 2006, 34% of the treated 
uncomplicated hypertensive patients were assessed to have their BP controlled to 
below 140/90 mmHg in 2006. By adding one ordinary BP-lowering drug with a half 
standard dose for those with a systolic BP of 140 mmHg or more or diastolic BP or 
90 mmHg or more would improve the control of hypertension (BP < 140/90 mmH) 
from 34% to 48%. This would reduce strokes by 18% and IHD events by 13%.  In 
case one to two half standard doses of an ordinary BP-lowering drug were added for 
those with uncontrolled BP, when needed, the control of hypertension would 
increase up to a level of 67%. This would reduce strokes by 28% and IHD events by 
21%. 
 
The impact on BP control after intensifying the treatment, when needed, with one to 
two half standard/standard doses of ordinary antihypertensive regimen in 2006 is 
shown in Figure 5. 
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Figure 5. Impact on blood pressure (BP) control after intensifying treatment, when 
needed, with one to two half standard/standard doses of ordinary antihypertensive 
regimen in 2006. Distribution of primary BP is shown with full lines. Theoretical 
distribution of BP after intensification of treatment with one half standard dose, one 
standard dose, one to two half standard doses, and one to two standard doses, when 
needed, is shown with dashed lines. No drugs were added if a BP was already below 
140/90 mmHg. The second drug was added only if the control target of hypertension 
(BP<140/90 mmHg) was not achieved with the first drug add-on therapy. Percentages on 
the left shows control of BP before intensification the drug therapy; percentages on the 
right shows data thereafter. Modified from Ahola et al. Eur J Prev Cardiol 2012, 19:712-
722 (III). 
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5.4 Antihypertensive drug therapy in Finland between 2000  
      and 2006 
5.4.1 Diabetic patients (I) 
 
The average number of BP-lowering drugs increased from 1.15 to 1.5 among all 
diabetic patients, and from 2.05 to 2.3, among those using antihypertensive drugs. 
Monotherapy decreased and combination therapy, especially the use of at least three 
BP-lowering drugs, increased significantly. During both years observed, the agent 
most frequently used in monotherapy was a BB or an ACE-inhibitor, whereas the 
drugs most frequently used in combination therapy were diuretics combined with 
BBs or ACE-inhibitors. The most often prescribed combination of at least three 
antihypertensive drugs, on the average, was a combination of diuretics, BBs and 
ACE inhibitors. Use of ARBs on the average tripled in monotherapy and in 
combination therapy. Utilization of either an ARB or an ACE-inhibitor was 
increased by 25-46%. Prescriptions of BBs, CCBs, and diuretics increased to a 
lesser degree. Utilization of BP-lowering drugs among diabetic patients receiving 
antihypertensive drugs in 2000 and in 2006 is shown in detail in Article I, Tables 3 
and 4. 
 
5.4.2 CHD patients (II) 
 
Monotherapy decreased and combination therapy, especially the use of at least three 
BP-lowering drugs, increased. The average number of BP-lowering drugs increased 
from 1.3 to 1.5 among all CHD patients, and from 1.8 to 2.0 among those using 
antihypertensive drugs. During both years observed, the agents most frequently used 
in monotherapy were BBs (approximately three-quarters), while the drugs most 
frequently used in combination therapy were BBs combined with diuretics or ACE-
inhibitors. The combination of at least three drugs most often prescribed was a 
combination of diuretics, BBs, and ACE-inhibitors. Use of ARBs on an average 
quadrupled in monotherapy and tripled in combination therapy. Utilization of BP-
lowering drugs among CHD patients receiving antihypertensive drugs in 2000 and 
in 2006 are shown in detail in Article II, Tables 3 and 4. Recent CHD patients, as 
compared with those with a longer history of CHD, used more BBs and RAS 
blockers, although recent CHD patients had less comorbidities than their 
counterparts. Yet, the total number of antihypertensive drugs was essentially similar 
among these two groups of patients (Article II, Table 5).  
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5.4.3 Uncomplicated hypertensive patients (III) 
 
The average number of BP-lowering drugs increased from 1.75 to 1.82 among 
treated uncomplicated hypertensive patients (from 1.95 to 2.14 among treated 
moderately to severely hypertensives and from 1.42 to 1.51 among treated mildly 
hypertensives).  
The prescribing pattern for monotherapy regimen decreased while combination 
antihypertensive medication increased. The use of RAS blockers was increased 
more than 40%. The use of ARBs was more than doubled in monotherapy and 
increased two- to three-fold in combination therapy. Thereby, ARBs became the 
thirdly popular drugs after BBs and diuretics while ACE-inhibitors dropped from 
third to fifth place after CCBs. Use of BBs decreased, although they still remained 
most frequently used drugs among uncomplicated hypertensive patients. Utilization 
of diuretics increased, while utilization of ACE-inhibitors and CCBs decreased. The 
two-drug combination most frequently used became an ARB combined with a 
diuretic. The combination of at least three drugs most often prescribed became a 
combination of diuretics, BBs, and ARBs. Utilization of BP-lowering drugs among 
uncomplicated hypertensive patients receiving antihypertensive drugs in 2000 and in 
2006 are shown in detail in Article III, Tables 1 and 2. 
 
5.5 Changes in the utilization of antihypertensive drugs and  
      concomitant diseases on the individual level between 2000  
      and 2006 (IV) 
5.5.1 Subjects with moderate to severe hypertension 
 
Among 274 791 moderately to severely hypertensive individuals the prevalence of 
diabetes increased 57%, to a level of 20%, and CHD increased 39%, to a level of 
18%. The prevalence of CHF and cardiac arrhythmias increased to a lesser degree 
(see Article IV, Table 1, Group 1).  
The mean number of antihypertensive drugs increased from 2.0 to 2.3. Monotherapy 
decreased from 36% to 24%, and combination therapy with at least 3 or more 
antihypertensive drugs increased from 30% to 42%. BBs remained the most 
frequently used antihypertensive drugs in monotherapy and in combination therapies, 
although the use of ARBs increased by 146%. The 2-drug combination used most 
frequently in 2000 and 2006 was a BB combined with a CCB (26% and 22%). 
However, for a 2-drug combination in 2006, 29% used a combination of a RAS 
blocker (ACE inhibitor or ARB) and a diuretic, while 19% used a combination of a 
RAS blocker and a BB. The most frequently used combination of at least 3 drugs, in 
2006, became a combination of BBs, diuretics, and CCBs (27% of those using more 
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than 2 drugs), while 50% used a combination including RAS blocker(s), diuretic(s), 
and BB(s) and 34% used a combination including RAS blockers(s), diuretic(s), and 
CCB(s) (Article IV, Table 2, Group 1). 
 
5.5.2 Subjects with uncomplicated mild hypertension 
 
Among 70 185 uncomplicated mild hypertensive individuals, who did not develop 
diabetes or cardiac diseases during the follow-up time, the mean number of 
antihypertensive drugs increased from 1.4 to 1.7 (Article IV, Table 1, Group 2). 
Monotherapy decreased from 67% to 51% and combination therapy with at least 3 
or more antihypertensive drugs increased from 8% to 17%. BBs clearly remained 
the most frequently used drugs in monotherapy and in combination therapies, 
although the use of ARBs increased by 140%. The 2-drug combination used most 
frequently in 2000 and 2006 remained another 2-drug combination (mostly a 
combination of two different diuretics; a thiazide diuretic combined with a 
potassium-sparing diuretic). However, for 2-drug combinations in 2006, 27% used a 
combination of a RAS blocker and a diuretic, while 16% used a combination of a 
BB and a diuretic. In combination therapy with at least three BP-lowering drugs, a 
combination including BB(s), diuretic(s), and ARB(s) became the most common 
(19%). 36% used a combination including RAS blocker(s), BB(s), and diuretic(s) 
whereas 16% used a combination including RAS blocker(s), CCB(s), and diuretic(s) 
(Article IV, Table 2, Group 2). 
 
5.6 Differences in utilization of antihypertensive medication in  
      2006 between recently and formerly diagnosed subjects  
      with moderate to severe hypertension (IV) 
 
Recently diagnosed moderately to severely (RDMS) hypertensive subjects used on 
the average 2.1 antihypertensive drugs, which was 10% less than that used by 
formerly diagnosed moderately to severely (FDMS) hypertensive subjects. Thus, the 
prevalence of diabetes, CHD, and CHF were essentially similar among these two 
patient groups. RDMS hypertensives were more often on monotherapy (+25%) and 
on 2-drug combination therapy (+7%) and less (-23%) on combination therapy with 
three or more BP-lowering drugs than were the FDMS hypertensive subjects. 
Among RDMS hypertensives, the most frequently used antihypertensive drugs were 
the diuretics, followed by BBs, CCBs, ARBs, and ACE-inhibitors. Among FDMS 
hypertensives, the most frequently used antihypertensive drugs were the BBs, 
followed by diuretics, CCBs, ACE-inhibitors, and ARBs. Thus, the RDMS 
hypertensives used 14% less BBs, 8% less diuretics, 16% less CCBs, and 14% less 
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ACE-inhibitors but 27% more ARBs than the FDMS hypertensive subjects. (Article 
IV, Table 3). 
 
In monotherapy, the BBs, followed by ACE-inhibitors and CCBs, were the most 
frequently used BP-lowering drugs among RDMS hypertensives as well as among 
FDMS hypertensives. Still, the RDMS hypertensives used 130% more ARBs on 
monotherapy and 67% more 2-drug combination of ARBs and diuretics than the 
FDMS hypertensives. The most frequently used 2-drug combination among the 
RDMS hypertensives was a diuretic combined with an ARB (23%), while among 
the FDMS hypertensives that was a combination of a CCB and a BB. However, a 
combination including a RAS blocker and a diuretic was used by 37% and 31% of 
the RDMS and FDMS hypertensives, respectively. In combination therapy with at 
least three BP-lowering drugs, a combination including diuretic(s), BB(s), and 
ARB(s) became the most common (27%) among the RDMS hypertensives while 
among the FDMS hypertensives that was a combination including diuretic(s), BB(s) 
and CCB(s) (27%). However, a combination including RAS blocker(s), diuretic(s), 
and BB(s) was used by 48% and 49% and a combination including RAS blocker(s), 
diuretic(s), and CCB(s) by 34% and 35% of the RDMS and FDMS hypertensives, 
respectively (Article IV, Table 4). 
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6 Discussion  
6.1 Utilization of antihypertensive drugs and control of  
      hypertension among diabetic patients in Finland between  
      2000 and 2006 (I) 
 
In 1994 the FHA working group guidelines 32 recommended ACE inhibitors for 
initial antihypertensive medication for diabetic patients, especially if nephropathy 
was related. The FCCH guidelines published in 2002 12 and updated in 2005 13 
recommended all major antihypertensive agents, although RAS blockers were 
preferred in case of diabetic nephropathy. The ESH guidelines published in 2003 16, 
stated that all well tolerated and effective agents can be used, although it also 
favored ACE inhibitors for Type 1 diabetic nephropathy and ARBs for Type 2 
diabetic nephropathy. The JNC7 18, published in 2003, recommended BBs only in 
case of concomitant ischaemic heart disease whereas the FCCH guidelines, updated 
in 2005, noted that thiazide diuretics and BBs 107 without intrinsic sympathomimetic 
activity may increase blood glucose level but improve diabetic patients prognosis 8.  
 
RAS blockers may offer additional vasculoprotective benefits to high-risk diabetic 
patients beyond BP control 31, 40, 74. There is evidence that RAS blockers retard the 
development and/or progression of diabetic nephropathy 40, 71, 72, 172. Since 2007, 
guidelines have recommended RAS blockers as a compelling indication for diabetic 
patients. On the other hand, many studies support the view that the reduction of BP 
per se is more important than the individual properties of the specific drug, for 
decreasing cardiovascular risk among most hypertensive diabetic patients 8, 9. 
According to recent evidence, however, no benefit is achieved except for those at a 
high risk of stroke, if the systolic BP is lowered intensively below 130 mmHg 41, 42, 
or below 120 mmHg 43, as compared with those with target systolic BP <140 mmHg. 
The FCCH guidelines 12 lowered the target BP for diabetic patients from 140/90 
mmHg to 140/80 mmHg not earlier than 2002, although the WHO-ISH ESH 
guidelines 45 published already in 1999 stated that the desirable BP goal for diabetic 
patients is below 130/85 mmHg. Beyond that in 2003 the JNC7 18 and the ESH 
guidelines 16 lowered the target BP below 130/80 mmHg, which was still the current 
international recommendation during the year 2006. However, the national 
recommendation in 2006 was to lower the BP below 140/85 mmHg according to the 
FCCH guidelines 13 updated in 2005.  
 
According to the present study (I), during the early 2000s, 80% of the Finnish adult 
diabetic patients were hypertensive. Two-thirds of them were receiving 
antihypertensive medication and 31% of the treated hypertensive diabetic patients 
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had their BP reduced to below 140/90 mmHg and only 14% below 130/80 mmHg. 
CHF was independently associated with better control of hypertension. This is quite 
understandable considering the impaired left ventricular ejection fraction and 
reduced cardiac output and/or antihypertensive polypharmacy of patients with CHF. 
However, age, gender, BMI, smoking, alcohol consumption, BP-lowering or lipid-
lowering drug therapy, number of antihypertensive drugs, or any other comorbidities 
were not associated with better control of BP.  
 
Between 2000 and 2006, monotherapy as well as utilization of exactly two 
antihypertensive drugs decreased relatively because combination therapy, especially 
the use of three or more antihypertensive drugs, increased significantly. Use of 
ARBs on the average tripled while the use of RAS blockers increased from 59% to 
74%. In the early 2000s, according to the Health 2000 Survey, three-quarters of the 
hypertensive diabetic patients with nephropathy used either ACE-inhibitors or ARBs.    
During both observed years the agent most frequently used in monotherapy was a 
BB or an ACE-inhibitor, whereas the drugs most frequently used in combination 
therapy were diuretics combined with BBs or ACE-inhibitors. The use of renin-
angiotensin system blockers was increased by 25-46% due to a three-fold increase in 
the utilization of ARBs. Combination therapy with RAS blockers together with 
diuretics increased by approximately 40% to a level of 40%, and the combination of 
RAS blockers with CCBs increased by 60% to a level of 22%. This increasing trend 
in the combination therapy with RAS blockers and diuretics or CCBs is favorable 
and in accordance with evidence-based data from trials 31, 74 and national and 
international guidelines 13, 19. The most frequently used combination of at least three 
antihypertensive drugs in 2000 and in 2006 was a combination of diuretics, BBs, 
and ACE-inhibitors, although the use of this combination decreased relatively 
between 2000 and 2006 because in many cases ACE-inhibitors seemed to be 
replaced by ARBs. It is speculative but possible that the skills of the physicians in 
the management of hypertension, as a consequence of the treatment guidelines, have 
improved. On the other hand, increased production and vigorous marketing of well 
tolerated ARBs could largely explain the change observed in combination therapy. 
 
According to the results of this study, the prevalence of hypertension among Finnish 
adult diabetic patients in the early 2000s was higher and the control of hypertension 
lower than those observed in other population studies in US, Mexico, and Sweden  
133, 136 146, 173. Moreover, in the beginning of the last decade, hypertensive diabetic 
patients in Finland were prescribed more BBs and diuretics and as much or less RAS 
blockers than was prescribed in UK 128 and US 139. The results of this study are in 
line with several previous studies demonstrating underutilization of RAS blockers 
128, 174, 175. However, there is evidence that the use of RAS blockers has increased 
from the 1990s to 2000s 128, 162, 164. Despite the fact that evidence-based drug 
therapies have increased among Finnish diabetic patients, there is a still need for 
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more rational antihypertensive medication. For example, of the diabetic patients 
using BBs, only 40% in 2000 and 36% in 2006 had CHD. Furthermore, of those 
receiving antihypertensive drugs, without CHD, still 43% in 2000 and 47% in 2006 
used BBs, which indicates relative overutilization of BBs among hypertensive 
diabetic patients. These findings highlight that physicians should take into account 
more precisely the individual characteristics and comorbidities when selecting 
antihypertensive agents for diabetic patients. The significance of the high utilization 
rate of BBs in the development of new-onset diabetes in Finland requires further 
investigation.  
 
6.2 Utilization of antihypertensive drugs and control of  
      hypertension among CHD patients in Finland between  
      2000 and 2006 (II) 
 
A BB has been the drug of choice for hypertensive CHD patients, and Finnish 
national guidelines 12, 13, 32 have recommended their primary use in each guideline. 
Since JNC6 17, with minor exceptions, ACE inhibitors, as antihypertensive drugs, 
have been a compelling indication for CHD after MI. However, FCCH guidelines in 
2002 12, and in 2005 13, recommended ACE inhibitors as a possible indication but 
not as a compelling indication until in most recent guidelines published in 2009 14. 
ARBs have become competitive drugs for the ACE inhibitors since the ESH/ESC 
guidelines, published in 2007, although the FCCH guidelines in 2009 14 have 
recommended their use in case the ACE inhibitor is not tolerated.   
  
According to meta-analyses of six randomized placebo-controlled trials, treatment 
with ACE-inhibitors reduces all-cause mortality, cardiovascular mortality, and 
nonfatal MI, among CHD patients with preserved left ventricular function 112. 
According to the HOPE study, the ACE-inhibitor Ramipril reduced the rate of 
cardiac death and MI by 20% among high-risk patients 46. ARBs have proven to be 
non-inferior when compared with ACE-inhibitors in the prevention of CV events 67, 
83, 85. Still, for patients with hypertension and stable angina pectoris, the first drug of 
choice is a BB 176. However, the benefit can also be obtained with different drugs 
and drug combinations, including CCBs, and it appears to be related to the degree of 
BP reduction 66.  
 
According to the present study (II), during the early 2000s, three-quarters of the 
CHD patients were hypertensive and nearly 90% of them used antihypertensive 
medication. Of those receiving antihypertensive drugs, one quarter had the BP 
reduced below 140/90 mmHg and 9% had a BP less than 130/80 mmHg. According 
to Finnish national guidelines 12, 32 the target BP for CHD patients (as with the 
general population) was below 160/90 mmHg in 2000 and below 140/85 mmHg in 
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2006. On the other hand, according to international guidelines (JNC6 17), the target 
BP below 140/90 mmHg was the current recommendation among CHD patients 
before and during the follow-up time 2000-2006. This target, because of inconsistent 
evidence, still seems essentially reasonable as reappraised in recent guidelines 7.  
 
Between 2000 and 2006, the use of RAS blockers increased markedly, mostly 
because of the more than three-fold increase in the use of ARBs. Owing to the 
increased use of ACE-inhibitors and ARBs, combination therapy with RAS blockers 
together with diuretics, BBs, and CCBs increased, which is in accordance with 
evidence-based data from trials and national and international guidelines 13, 19, 66, 176, 
177. Still, RAS blockers seemed to be underused among hypertensive CHD patients. 
BBs, instead, were already comparatively frequently used in 2000 and increased 
only by 5%, to a level of 77-79%, by the late 2006.   
 
Earlier national studies in Europe have shown inadequate risk factor management 
for patients with CHD: PREVESE I and II studies in Spain 150, 166, Usik and 
PREVENIR in France 178, TASPIC-CRO study in Croatia 154, a national survey in 
Switzerland 151, and Euroaspire surveys I-III in eight European countries 148 (Finland 
being one of the participating countries). The results of the present study (III) are in 
line with the Euroaspire surveys 148, national surveys in Switzerland 151 and France 
178, showing high prevalence of BBs and underutilization of RAS blockers. However, 
in this study, BBs were used more frequently but ACE-inhibitors less frequently 
than in earlier studies in Spain 150, France 178, Croatia 154, and Switzerland 151, in the 
beginning of the 2000s. On the other hand, results of this study are in line with the 
Euroaspire surveys by showing an increase in the use of BBs, RAS blockers, and 
diuretics, although all major antihypertensive agents were used less frequently than 
on the average in the recent Euroaspire survey 148, 149. However, the utilization of 
diuretics in Finland, according to Euroaspire II, was exceptionally low (12%), and 
contrary to the other European countries, the use of diuretics even decreased in 
Finland, to a level of 11%, between 1999-2000 and 2006-2007 149. The results of the 
present study are not in line with these figures concerning the utilization of diuretics 
among CHD patients in Finland. Quite on the contrary, utilization of diuretics 
among Finnish CHD patients also increased but not as much as in many other 
European countries. It is worth noting that the studies in the Euroaspire surveys 148 
were limited to outpatients ≤ 70 years of age who had a history of MI or acute 
coronary syndromes or coronary revascularization.       
   
It seems that evidence-based drug therapies have increased among Finnish CHD 
patients between 2000 and 2006. As an example, recent CHD patients were 
prescribed BP-lowering drugs in 2006 more rationally (i.e., more BBs and more 
RAS blockers were used) than were those with longer history of CHD. It is 
speculative but possible that the skills of the physicians in the management of 
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hypertension, as a consequence of the recent guidelines, have improved. This is 
supported by the findings, which show that even among same individuals the 
utilization of RAS blockers has increased from late 2000 to late 2006. Though, 
aging and increased prevalence of diabetes, hypertension, and other comorbidities 
might have also increased their usage. On the other hand, increased marketing of 
well tolerated ARBs, alone or in combination with diuretics, could largely explain 
the changes in combination therapy.  
 
6.3 Utilization of antihypertensive drugs, control of  
      hypertension and achievable reduction in BP and   
      cardiovascular morbidity among uncomplicated  
      hypertensive patients in Finland between 2000 and 2006 (III) 
 
The FCCH guidelines 12-14 and JNC6 17 have specified antihypertensive medication 
for uncomplicated hypertensive patients. In other guidelines, uncomplicated 
hypertensive patients have been included with patients with essential or primary 
hypertension. The FCCH guidelines published in 2002 12 recommended starting 
antihypertensive medication with low-dose thiazides, ACE inhibitors, or BBs, for 
uncomplicated hypertensive patients. CCBs and ARBs were optimal in specific 
cases. In 2005, FCCH guidelines 13 stated that the treatment of uncomplicated 
hypertension can be initiated with RAS blockers, BBs, diuretics, and CCBs. 
However, it noted the poor evidence of benefits with BBs in the treatment of 
uncomplicated hypertension. In combination therapy, the FCCH guidelines in 2005 
13 noted that most drugs can be combined. 
 
Between 2000 and 2006, the number of treated adult uncomplicated hypertensive 
patients increased from nearly 430 000 to more than 590 000 while the mean 
number of antihypertensive drugs increased from 1.7 to 1.8. At the same time 
monotherapy decreased and combination therapy increased. The proportion of 
mildly hypertensives nearly doubled while moderately to severely hypertensives 
increased only slightly. The increase of subjects treated for milder forms of 
hypertension suggests that clinicians have complied with national and international 
guidelines in that respect. On the other hand, the increase of subjects treated for 
milder forms of hypertension can also be interpreted that the criteria for the 
reimbursement of hypertension medication costs conceded by the SII meets the 
criteria of clinical hypertension set by international and national guidelines even less 
than before 13, 16.  
 
According to the results of this study (III), the use of RAS blockers increased more 
than 40% because the use of ARBs more than doubled in monotherapy and 
increased two-fold to three-fold in combination therapy. Thereby, ARBs became the 
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thirdly popular drugs after BBs and diuretics while ACE-inhibitors dropped from 
third to fifth place after CCBs. Use of BBs decreased, although they remained the 
most frequently used drugs among uncomplicated hypertensive patients without 
specific indications for their use. Utilization of diuretics, especially thiazide diuretics, 
increased due to their frequent use in combination therapy with ARBs. In fact, by 
the end of 2006, the two-drug combination most frequently used was an ARB 
combined with a diuretic, which is in line with the findings from RCT trials 73 and 
guidelines 7, 16. The combination of at least three drugs most often prescribed 
became a combination of diuretics, BBs, and ARBs. British Hypertension Society 
Guidelines, published two years earlier, in 2004, recommended a blocker of renin-
angiotensin system, a CCB, and a thiazide-diuretic, as a  three-drug combination, 
which is still in line with the recommendations of recent European Guidelines on 
Hypertension Management published in 2009 7.  
 
It seems that, as first-line agents, BBs (especially among mildly hypertensives) were 
chosen more frequently than other antihypertensive agents. The status of BBs as 
first-line agents has been impugned. British Hypertension Society Guidelines for 
hypertension management, for instance, placed BBs within brackets in the AB/CD 
algorithm in 2004 177. However, recently published hypertension guidelines 7 have 
stated that BBs can initiate the treatment of hypertension, even in monotherapy. Still, 
recent guidelines have acknowledged, and there is evidence, that BBs decrease the 
risk of stroke less than other antihypertensive agents, especially among elderly 
patients 98.  Accordingly, BBs and especially combinations of BBs and diuretics 
should be avoided as primary treatment among individuals with a metabolic 
syndrome or increased risk for new-onset diabetes 99-101. Worth considering is the 
fact that a combination of a BB and a diuretic was still on the list of efficient and 
well tolerated two-drug combinations in the hypertension guidelines published in 
2003 16.  In Finland in 2000-2006, fortunately, concerning two-drug combinations, a 
combination of a BB and a diuretic retreated from third to fourth place during the 
follow-up time.  
 
Studies published earlier, concerning treated uncomplicated hypertensive patients 
have either involved a relatively small number of patients or have been made in 
special clinics or have included hypertensive patients only with a certain stage, and 
are therefore not comparable with this study. To date, this is the first longitudinal 
study prescribing in detail the use of different antihypertensive drug combinations 
(including three or more antihypertensive drugs) among adult treated uncomplicated 
hypertensive patients at a population based level. 
 
It is well known that a combination therapy is usually required to achieve a proper 
control of BP whereas a low-dose combination therapy increases the efficacy and 
reduces adverse effects of the treatment 6, 7, 103. According to the results of the 
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present study, only one-third of the treated uncomplicated hypertensive patients 
were assessed to have their BP controlled to below 140/90 mmHg in 2006.  By 
applying Law’s meta-analyses to the results of the present study, an addition of only 
one-half standard dose, when needed, for subjects with a BP ≥ 140/90 mmHg, would 
improve the control of hypertension from one-third to 48%. This, accordingly, 
would reduce the incidence of strokes by 18% and ischaemic heart disease events by 
13%. Therefore, more abundant antihypertensive treatment is evidently needed in 
order to improve the control of hypertension and to decrease cardiovascular 
morbidity among uncomplicated hypertensive patients.   
 
The threshold for the reimbursement for hypertension medication costs in Finland is 
much higher than the thresholds for antihypertensive drug treatment presented in 
national 13 and international 19 guidelines. On the other hand, treatment of 
cardiovascular complications is a significant burden for the Finnish health care also 
from the financial point of view. Quite on the contrary, intensified antihypertensive 
treatment would substantially reduce cardiovascular morbidity among 
uncomplicated hypertensive patients. Beyond that, the entitlement to reimbursement 
for hypertension medication costs by lowering the patient’s expenses would 
probably increase the treatment compliance. Under these circumstances it seems 
reasonable to recommend lowering the threshold for the reimbursement of 
hypertension medication costs in Finland. To what level precisely, from the public 
economic point of view, however, requires further clarification.  
 
6.4 Beta-blockers are relatively overused in Finland (IV) 
 
The guidelines of the nineties (FHA working group 32 and JNC6 17) recommended 
the initiation of antihypertensive medication with a diuretic or a BB unless 
contraindicated or specifically indicated for another drug. In 2002, the FCCH 
guidelines 12 recommended the initiation of antihypertensive medication with low-
dose hydrochlorothiazides, ACE inhibitors, or BBs. According to national and 
international guidelines since the early 2000s, each agent can be preferentially 
prescribed under specific conditions 13, 14, 16. The FCCH guidelines, published in 
2002 12 (updated in 2005 13), and the ESH and ESC guidelines for the management 
of arterial hypertension, published in 2003 16, demonstrated evidence that specific 
drug classes may differ in some effect or with special groups of patients. However, 
the ESH guidelines stated that the main benefit of antihypertensive therapy is due to 
lowering BP per se 16. Nevertheless, guidelines have emphasized that physicians 
should tailor the drug treatment for the individual patient after taking into account 
the patient’s cardiovascular risk profile, target organ damage, and other coexisting 
disorders, as well as the indications and contraindications of the specific drug 
classes 13, 16. Beyond that the ESH guidelines 16 emphasized the importance of low-
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dose combination therapy and established the renoprotective effects of RAS 
blockers 16. However, since then the status of BBs as first line agents has been 
impugned. The AB/CD algorithm, for example, was brought out in 2004 177. 
According to meta-analyses of Lindholm et al, BBs should not be used as first 
choice in the treatment of primary hypertension. Furthermore, there is evidence that 
BBs decrease the risk of stroke less than other antihypertensive agents, especially 
among elderly patients. Besides, the ESH/ESC guidelines 19 suggested that BBs and, 
especially, combinations of BBs and diuretics should be avoided as primary 
treatment among individuals with a metabolic syndrome or increased risk for new-
onset diabetes.  
 
This study (IV) is the first study providing longitudinal nationwide data of the 
utilization of antihypertensive medication for subjects treated for moderate to severe 
hypertension and mild uncomplicated hypertension, in relation with changes in 
concomitant disease profiles at the individual level. According to the results of this 
study, among moderately to severely hypertensives (Group 1) as well as among 
uncomplicated mild hypertensives (Group 2), the mean number of antihypertensive 
drugs increased on the average by 0.3. Accordingly, monotherapy decreased while 
combination therapy increased. There are some possible explanations for these 
changes. Firstly, combinations of two drugs in a single tablet, which improve 
medication compliance 102, have become widely available during the last decade. 
Secondly, the majority of clinicians might have been influenced by the guidelines 
emphasizing the importance of combination therapy 13, 16. Thirdly, in this study, 
patients in groups 1 and 2 became 6 years older, which probably increased the need 
for additional drugs, because higher age increases systolic BP. Fourthly, moderately 
to severely hypertensives (Group 1) developed more concomitant diseases, 
especially diabetes and CHD, which very likely called for more frequent and more 
effective drug therapy. Among uncomplicated mild hypertensives (Group 2), new-
onset of diseases can not explain the increase in drug therapy, because existence of 
diabetes and cardiac diseases were excluded during the whole period of observation.  
 
Utilization of BBs increased between 2000 and 2006, and they remained clearly the 
most frequently used antihypertensive drugs in both groups. This relative overuse of 
BBs was more outstanding among uncomplicated mild hypertensives (Group 2), 
although the patients had no compelling indication for the use of BBs. It is possible 
that vigorous marketing of BBs, particularly methoprolol, in the 1990s and early 
2000s, is one probable reason for the high utilization of BBs.   
 
The utilization of ARBs increased remarkably. There are several reasons for this: 
Firstly, the beneficial effects of ARBs, which go beyond the BP-lowering effect,  
has been proven at several trials and presented widely in the preceding guidelines 16, 
19. Secondly, fixed combinations of two drugs, particularly those of a RAS blocker 
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combined with a thiazide diuretic, has increased during the recent years. On the 
other hand, among moderately to severely hypertensives, the prevalence of ACE 
inhibitors even decreased slightly during the follow-up time. Obviously quite often 
ACE inhibitors have been replaced by increasingly marketed ARBs, which are better 
tolerated.  
 
The RDMS hypertensives used slightly less antihypertensive drugs than the FDMS 
hypertensives (2.1 vs. 2.3 per day) despite having essentially a similar burden of 
concomitant diseases. Diuretics, followed by BBs, were the most frequently used 
drugs for RDMS hypertensives, while for FDMS hypertensives, they appeared in 
reverse order. As expected, in monotherapy and in 2-drug combinations, ARBs and 
RAS blockers were clearly used more frequently for RDMS hypertensives than for 
FDMS hypertensives. However, concerning at least 3-drug combinations, a RAS 
blocker combined with a diuretic and a CCB was used less frequently for RDMS 
hypertensives than for FDMS hypertensives. It seems that, even for RDMS 
hypertensives, RAS blockers are prescribed as second-line or third-line drugs after 
BBs. Beyond that, monotherapy was more common for RDMS hypertensives than 
for FDMS hypertensives, which indicates that the RDMS hypertensives must have 
had milder hypertension and thereby less need for antihypertensive medication than 
the FDMS hypertensives. This, however, on the ground of missing BP 
measurements, is disputable. Anyhow, shorter history of hypertension could indicate 
milder hypertension. Beyond that it is possible that non-pharmacologic treatment of 
the RDMS hypertensives is more powerful than the treatment of those with a longer 
history of antihypertensive pharmacotherapy. Another explanation could be that, due 
to a recent diagnosis, the RDMS hypertensives have not had time to acquire the 
intensification of pharmacotherapy. Nevertheless, quite surprisingly, also for the 
RDMS hypertensives, BBs were clearly the most frequently used drugs in 
monotherapy. Besides, in monotherapy, the RDMS hypertensives used relatively 11 
percent more BBs than did the FDMS hypertensives. Only approximately one fifth 
of the RDMS hypertensives had a compelling indication for BBs. Still, 
approximately one-half of all RDMS hypertensives and one-third of those on 
monotherapy used BBs. 
 
However, despite the substantial differences in methodology, earlier studies share 
some similarities with our recent study. Results of this study are in line with earlier 
studies demonstrating a significantly increasing trend in the use of antihypertensive 
agents 179. A relatively high prevalence of BBs, on the average 62%, has been 
reported in four European countries: Belgium, Germany, Switzerland, and Sweden 
180. In monotherapy, BBs in the present study, in 2006, were used more frequently 
than in Portugal, Canada, and England 181-183. However, among newly treated 
hypertensive patients, BBs were used as first-line agents in Sweden and in the 
Netherlands even more frequently than for the recently diagnosed moderately to 
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severely hypertensives in the present study 160. It seems that BBs are more 
frequently used in the Northern European countries. Accordingly, RAS blockers 
were prescribed in Finland, in monotherapy and in 2-drug combinations, less than in 
Portugal, Canada, and England 181-183. According to the results of this study, a 
preferred 3-drug combination (a RAS blocker plus a CCB plus a diuretic) was used 
by 11-22% of the subjects in 2006.  However, the corresponding figure was 31% in 
England 183 and 45% in Portugal 181. The European Society of Hypertension 
guidelines 7 and Finnish Current Care Hypertension guidelines 14 did not state 
clearly the preferred 3-drug combinations until in 2009, although a blocker of renin-
angiotensin system and a CCB and a thiazide-diuretic was already stated as a 
recommended 3-drug combination in the British Hypertension Society Guidelines in 
2004 52. 
 
Treatment guidelines of hypertension are insufficiently followed, particularly among 
those with a longer history of antihypertensive pharmacotherapy, which indicate that 
physicians do not easily change their drug prescribing routines.  
 
6.5 Limitations 
 
Firstly, BP was measured only in the population-based H2000 survey in 2000-2001. 
BP levels in 2006 instead are less reliable because they were not clinically measured 
but calculated by linking the H2000 survey and the database data of SII together and 
taking into account changes in age, sex, and drug utilization (mean number of BP-
lowering drugs) of the target population between late 2000 and late 2006.  
 
Secondly, BP was determined as a mean of two measurements made on a single 
occasion. However, there is evidence that multiple reading prevents overestimation 
of hypertension 184, 185 and therefore only two measurements made on a single 
occasion most obviously leads to an overestimation of hypertension and an 
underestimation of the control of hypertension.  
 
Thirdly, the expected reductions in BP levels and cardiovascular morbidity with 
add-on therapy is only theoretical. The formulae used in these calculations are based 
on the meta-analysis of 147 randomized trials in the context of expectations from 
prospective epidemiological studies 95, which, eventually, can only give a 
sophisticated estimation. 
 
Fourthly, all prescribed drugs purchased during the three months’ period in 2000, 
and in 2006, respectively, have been considered as regular use of these drugs. 
However, it is obvious that some of the patients interrupted their medication and/or 
in some of the cases the medication was changed during the three months’ period of 
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gathering. Thereby utilization of antihypertensive actually may have been even 
somewhat less than that shown by the database data of the SII. On the other hand, 
taking into account the fact that, on the average, the compliance of drugs is less than 
100%, it is possible that there have been some unidentified subjects who have 
purchased their drugs in the end of August and again in the beginning of December, 
but not during the 3 month period of data gathering, and thereby have not been 
accounted for in the database data of the SII.  
 
Furthermore, dosages of the antihypertensive drugs used were not available. In 
relation to the recommendations of use of the low-dose antihypertensive agents, 
especially in case of thiazides, quantitative analyses of specific drugs would have 
been beneficial. 
 
Finally, these studies may include some unidentifiable subjects using BP-lowering 
drugs not only for the treatment of hypertension but also for the treatment of other 
diseases, such as migraine and essential tremor. However, their proportion is 
estimated to be extremely low and would therefore not have any influence on the 
findings. However, the real utilization of antihypertensive drugs, especially BBs, has 
probable been a bit lower than described.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THL — Research 103, 2013 93 Antihypertensive Drug Therapy in Finland 
 
7 Summary and Conclusions 
The database of the SII included practically 100% of the prescriptions on 
antihypertensive and lipid-lowering drugs for the Finnish population during late 
2000 and late 2006. The drug utilization data from the database of SII proved to be 
basically in line with the data observed in the population-based Health 2000 Survey, 
and vice versa. Therefore, the results presented in this thesis can be considered 
accurate and reliable. 
 
Taking into account the target BP during these studies, this thesis indicates that the 
control of BP in the beginning of the 2000s has been alarmingly poor. Then again, 
between 2000 and 2006, utilization of antihypertensive regimens, especially in 
combination therapy, increased significantly. It seems that, among moderately to 
severely hypertensives, use of antihypertensive drugs became more frequent, 
probably because of aging and new-onset of diseases, especially diabetes and CHD. 
However, among uncomplicated mild hypertensives, utilization of antihypertensive 
drugs increased without changes in patients’ disease profiles, which suggests that 
clinicians have complied with guidelines in that respect. Furthermore, utilization of 
evidence-based drug therapies among adult hypertensive patients had increased 
significantly by the end of 2006, predicting benefits in cardiovascular morbidity and 
mortality in the future.  
 
In spite of positive trends in the utilization of antihypertensive drugs, especially in 
the case of RAS blockers, underutilization of antihypertensive drugs together with 
somewhat irrational drug selection, especially in monotherapy but also in 
combination therapies, remain matters of concern. For instance, even among 
recently diagnosed hypertensives, RAS blockers seem to be prescribed as second-
line or third-line drugs after BBs. In fact, there seems to be an unceasing relative 
overuse of BBs in the treatment of hypertension, especially among diabetic patients 
and uncomplicated hypertensive patients. Moreover, quite surprisingly, BBs seem to 
be chosen as first line agents far more often than other antihypertensive agents, even 
among recently treated hypertensives without compelling indication for their use. It 
seems that clinicians do not easily change their prescribing patterns.     
 
Retrospectively, referring to contemporary guidelines, antihypertensive drug therapy 
between 2000 and 2006 can be assessed to be poor in Finland. On the other hand, 
taking into account both recent and previous guidelines for hypertension 
management, antihypertensive drug therapy has nonetheless improved in Finland. 
However, treatment recommendations are still insufficiently followed. The reasons 
for this must be patient-related, physician-related and medical/healthcare system -
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related. Yet, the reasons are complex; clinical inertia is probably one of the major 
factors behind the lag.  
 
Briefly, more substantial antihypertensive treatment for high-risk and low-risk 
hypertensive adult patients in Finland is obviously needed. Furthermore, more 
rational selections of antihypertensive drugs are also called for. Physicians should 
take into account with greater precision related or absent comorbidities, 
cardiovascular risk factors, and other individual characteristics when choosing 
antihypertensive agents for hypertensive patients in clinical practice.  
 
However, as shown in this thesis, intensifying treatment of uncomplicated 
hypertensive patients whose BP is uncontrolled (≥140/90 mmHg), by only one- half 
standard dose of ordinary BP-lowering regimen, would increase the control of 
hypertension from 34% to 48%, reduce strokes by 18%, and reduce ischaemic heart 
disease events by 13%.  
 
Finally, the threshold for the reimbursement of hypertension medication costs does 
not meet with the BP threshold for drug therapy presented in national and 
international guidelines. However, the entitlement to reimbursement for 
hypertension medication costs by lowering the patient’s expenses would probably 
increase the treatment compliance. Better compliance would probably improve the 
control of hypertension which could decrease cardiovascular complications and their 
burden for the Finnish health care also from the financial point of view. 
Consequently, it seems reasonable to recommend lowering the threshold for the 
reimbursement of hypertension medication costs in Finland by taking into account 
also the fact that, during the past few years, the appearance of low-priced generic 
antihypertensive drugs has relatively lowered the expenses for the Social Insurance 
Institution of Finland as caused by patients entitled to reimbursement for 
hypertension medication costs. On the other hand, low-priced generic 
antihypertensive drugs have relatively lowered also patients’ expenses and thereby 
the role of the entitlement to reimbursement for hypertension medication costs has 
become less significant, especially from the patients’ financial point of view.  
Further investigation in the field of cost-effectiveness from the public health point of 
view is required in order to evaluate the optimal threshold and criteria for the 
reimbursement of hypertension medication cost. Yet, some of the results of Study III 
may be valuable for these evaluations. Anyway, the major findings of this thesis can 
be utilized in daily clinical practices, for the benefit of Finnish physicians and 
hypertensive patients in the long run.  
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